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Résumé 
La présente thèse comprend trois chapitres qui étudient la manière dont les éléments 
génétiques mobiles (EGMs), y compris les bactériophages (phages), peuvent être impliqués 
dans (i) l’adaptation des bactéries à différents mammifères, (ii) le parasitage des bactéries (par 
les phages) tout en préservant l’hôte bactérien, et (iii) le détournement des phages à des fins 
thérapeutiques (phagothérapie) pour traiter les infections bactériennes. 
Le premier chapitre s’intéresse au récent saut d’espèces de la souche humaine de 
Staphylococcus aureus du Complexe Clonal 8 (CC8) aux bovins, chez qui elle est responsable 
de mastites. Nous démontrons que le premier événement responsable de ce saut est 
l’acquisition d’une cassette chromosomique staphylococcique appelée  SCCbov. SCCbov est 
un EGM codant pour une nouvelle protéine de surface appelée « Adherence-Like Bovine 
protein » (ADLB) impliquée dans la pathogenèse des mastites. En effet, les souches de CC8 
bovines envahissent et tuent les cellules mammaires bovines en culture. Au contraire, 
l’excision de SCCbov ou l’inactivation d’ADLB diminuent la virulence dans ces conditions. Le 
second événement du saut est la perte d’un phage inséré dans le chromosome (ou prophage) 
qui interrompt le gène de la lipase. La restauration de l’activité lipase est susceptible de faciliter 
la croissance des staphylocoques dans le milieu riche en lipides du lait. Le troisième 
événement est la perte d’un prophage interrompant le gène de la β-hémolysine. La 
restauration de la β-hémolysine promeut la colonisation épithéliale. Enfin, nous avons construit 
des souches isogéniques de CC8 comportant différentes combinaisons de ces EGMs, 
permettant d’étudier le saut d’espèce dans une approche « d’évolution inverse ». En 
conclusion, c’est ce trafic d’EGMs qui est à l’origine du saut des CC8 humains aux bovins. 
Le second chapitre étudie la relation structure-fonction et la régulation de l’activité de la lysine 
du phage PlySK1249 de Streptococcus dysgalactiae. Les phages produisent des lysines en 
fin de réplication pour lyser les bactéries hôtes et libérer leur progéniture. Cependant, libérer 
les lysines dans l’environnement risque de lyser des bactéries voisines qui portent le même 
phage, ou des bactéries constituant de nouvelles proies. PlySK1249 a une structure multi-
modulaire intrigante, constituée d’un domaine central de liaison à la paroi bactérienne, encadré 
par un domaine amidase (bactériolytique) et domaine endopeptidase (CHAP; non-
bactériolytique). Nous démontrons que cette multi-modularité remplit trois fonctions. (A) la 
combinaison des deux domaines enzymatiques et du domaine de liaison est hautement 
synergique en termes de dégradation de la paroi et de lyse bactérienne. (B) le domaine de 
liaison prévient la diffusion de la lysine en la gardant liée aux débris de paroi cellulaire après 
la lyse bactérienne. (C) en présence de paroi bactérienne PlySK1249 est progressivement 
clivée et par une protéase de la paroi bactérienne (encore non-identifiée), qui désamorce son 
activité bactéricide. En résumé, la structure multi-modulaire de PlySK1249 implique une 
régulation inter-domaines sophistiquée, permettant de circonscrire la lyse à la cellule infectée 
afin de ne pas compromettre l’intégrité des cellules avoisinantes.  
Le troisième chapitre est une preuve de concept de la phagothérapie, utilisant un cocktail de 
12 phages anti-Pseudomonas aeruginosa et un modèle d’endocardite expérimentale (EE) 
chez le rat. Les phages se sont révélés hautement bactéricides in vitro (perte de >6 logs 
CFU/ml en 6 h), mais sélectionnaient des pseudomonas résistants. Les phages étaient aussi 
bactéricides in vivo (perte de >2 logs CFU/g de végétations en 6 h), mais ne sélectionnaient 
pas de résistance chez les animaux. L’absence de résistance in vivo était due au coût 
d’adaptation chez l’animal, car elle affectait la synthèse des pili et du LPS, deux facteurs de 
virulence critiques de pseudomonas. Enfin, la combinaison de phages et d’antibiotiques (dans 
ce cas la ciprofloxacine) s’est révélée hautement synergique, prévenant la résistance in vitro, 
et démontrant une fréquence de stérilisation des végétations cardiaques (>50% en 6 h) sans 
précédent dans l‘EE à P. aeruginosa. En conclusion, la phagothérapie combinée ou non aux 
antibiotiques ouvre des promesses nouvelles pour le traitement des infections bactériennes 
systémiques sévères.  
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Summary 
The present thesis comes in three chapters studying how mobile genetic elements (MGEs), 
including bacterial viruses called bacteriophages (phages), may be involved in (i) adaptation 
of bacteria to different mammalian hosts, (ii) parasiting bacteria (in the case of prophages) 
while preserving their bacterial hosts, and (iii) new therapeutic applications.  
The first chapter studied the recent human-to-bovine host jump of typical human 
Staphylococcus aureus Clonal Complex 8 (CC8) to cowherds, where it causes invasive 
mastitis. We show that the first event driving the human-to-bovine jump was the acquisition, 
by human CC8 strains, of a new “staphylococcal cassette chromosome” called SCCbov. 
SCCbov is a new MGE encoding for a new bacterial surface protein called Adherence-Like 
Bovine protein (or ADLB), which is implicated in mastitis pathogenesis. Indeed, while parent 
bovine CC8 readily invaded mammary cells lines, then escaped endosomes, and eventually 
lysed cultured cells, excision of SCCbov or knocking out ADLB decreased invasiveness and 
mammary cell death. We then show that the second event of the host-jump was the loss of a 
phage inserted in the bacterial chromosome (called a prophage), which interrupted the lipase-
encoding gene. The loss of this prophage restored S. aureus lipase activity, which is likely to 
facilitate staphylococcal growth in the lipid-rich milk milieu. The third event was the loss of a β-
hemolysin-interrupting prophage, restoring β-hemolysin activity, which was shown to promote 
epithelial colonization. Finally, we constructed isogenic bovine CC8 strains carrying these 
MGEs in various combinations, which will help determine the host-jump dynamics in a “reverse 
evolution” approach. Thus, MGE trafficking was the driving force behind the adaptation of 
human CC8 staphylococci to cows. 
The second chapter dissected the molecular structure-function activity and regulation of phage 
lysin PlySK1249 from Streptococcus dysgalactiae. Phages produce lysins at the end of their 
replication cycle to lyse host bacteria and release their progeny. However, uncontrolled 
diffusion of lysins in the surrounding might also lyse neighboring bacteria carrying sibling 
phages or potential new bacterial hosts. PlySK1249 has an intriguing multimodular structure 
with a central cell wall-binding domain (CWBD) bracketed by a bacteriolytic amidase domain 
and a non-bacteriolytic endopeptidase (CHAP) domain. We show that this multi-modularity 
serves a triple purpose. On the one hand, combining the two enzymatic and the CWBD 
domains led to a synergistic activity in cell wall degradation and bacterial lysis. On other hand, 
the CWBD prevented lysin diffusion after bacterial lysis by keeping lysin attached to cell wall 
debris. Finally, we found that in the presence (but not in the absence) of cell wall protein extract, 
PlySK1249 was subject to proteolytic cleavage by an as yet unknown bacterial wall protease, 
further introducing posttranscriptional modification in order to control its lytic activity. Thus, the 
multimodular structure of PlySK1249 implicates sophisticated inter-domain interactions 
promoting synergistic – yet cell-restricted – lysis, in order to release the phage progeny without 
jeopardizing neighboring host cells.  
The third chapter was a proof of concept study of phage therapy, using a cocktail of 12 phages 
directed against Pseudomonas aeruginosa and a model of P. aeruginosa experimental 
endocarditis (EE). Phages were highly bactericidal in vitro (loss of >6 logs CFU/ml in 6 h), but 
selected for phage resistance. Phages were also bactericidal in vivo (loss of >2 logs CFU/g of 
vegetations in 6 h), but did not select for resistance in animals. The absence of in vivo 
resistance selection was due to the fitness cost of resistance, which affected synthesis of 
bacterial pilus or LPS, two P. aeruginosa virulence factors that are critical for in vivo infection. 
Finally, combining phages with antibiotics (namely ciprofloxacin) was highly synergistic, 
prevented resistance selection in vitro, and cured notoriously difficult-to-treat EE due to P. 
aeruginosa at an unprecedented rate, healing >50% of the animals within 6 h of therapy. Thus, 
thoughtful utilization of phage therapy combined or not with antibiotics might become an 
alternative to treat severe systemic bacterial infections. 
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Executive summary  
 
Bacteria are unicellular organism classified in the domain of Prokaryota since they lack 
membrane bound organelles like nucleus. Prokaryotes are further divided in 
Eubacteria (referred to as bacteria below), and Archea, which are closer to eukaryotes 
in terms of DNA and enzymology. With a size ranging from 1 to 10 uM bacteria can 
adopt a variety of shapes including spherical (cocci) and rod-shaped (Bacilli), spiral-
shaped (spirochete) and comma-shaped (Vibrio). Also sexual reproduction is not 
observed, DNA transfer can occur horizontally via bacteriophage transduction, plasmid 
conjugation and transformation. As one of the first form of life on earth, bacteria 
colonized the major part of the environment including plants and animals. Bacteria 
colonizing animals, mainly in the gut and on the skin, outnumber the eukaryotic cells 
of the host. This microbiota is mainly composed of harmless or even beneficial bacteria 
having a positive impact on health by metabolising food compounds, training the 
immune system, synthetizing vitamins and providing direct protection against 
pathogens.   
Although most of the bacteria are harmless or beneficial to humans or animals, a 
minority of them is considered as pathogenic and cause infections. One of these 
pathogens is Staphylococcus aureus, a Gram-positive commensal bacterium that is 
found in approximately 30 % of healthy people who carry it asymptomatically in the 
nose, and also in numerous animal species including cows. This opportunistic 
pathogen can produce a large variety of disease in human, including skin and soft 
tissue infections, as well as life-threatening infections such as pneumonia, 
osteoarthritis, sepsis or endocarditis. Likewise, it is notoriously known to produce 
mastitis in cows. However, while S. aureus are quite ubiquitous in terms of host 
species, different animals tend to harbour different staphylococcal lineages. Several 
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studies suggested that critical modulators of this apparent host specificity might be 
related to DNA transfer and acquisition of novel exogenous genes that might be 
beneficial in specific environments, referred to as mobile genetic elements or MGEs. 
MGEs are DNA sequences that are or were able to mediate their own transfer from 
one genome to another. These elements include, bacteriophages (phages), 
pathogenicity islands, plasmids, transposons and staphylococcal cassette 
chromosome (SCC) in the case of staphylococci. Since these elements often harbour 
genes coding for virulence or resistance functions, their study can reveal how bacteria 
cause disease with important clinical implications.     
The present thesis was dedicated to study the implication of MGEs (including phages) 
in host adaptation, physiopathology and therapy from three standpoints: 
1. From the standpoint of the bacterium (in this case Staphylococcus aureus), 
which may acquire new genotypic and phenotypic properties via MGEs, and 
take advantage of these properties to jump from one host species to another. 
The question here was how MGEs have influenced the human-to-bovine host 
jump of the typical human S. aureus Clonal Complex 8 (CC8). 
2. From the standpoint of peculiar MGEs, i.e. phages and their chromosomal-
integrated “prophage” forms. Phages and prophages reunify bacterial-
dependent and bacterial-independent lifestyles, along which they can act either 
as bacterial predators (or lytic), commensals or symbionts (when integrated in 
the bacterial chromosome as prophages and provide useful genes), or 
temperate phages, which can switch from one phenotype to the other 
depending on environmental conditions. 
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The question here was how bacteriophages sharing both lifestyles can optimize 
their lytic enzymes in order to allow extrusion of their progeny by lysing the host 
bacteria and yet preserve neighbouring bacteria carrying sibling prophages, or 
potential new bacterial prey from collateral lytic damages. 
3. From the standpoint of therapy, purely predator (or lytic) phages have been 
used since a century to cure bacterial infections. While Eastern countries still 
use so called phage-therapy in their anti-infective arsenal, it was abandoned in 
Western countries to the benefit of antibiotics. However, the current threat of 
multiple antibiotic-resistant pathogens is reviving the interest in phage therapy 
as potential alternative strategy. 
The question here was whether phage therapy could demonstrate efficacy in 
the stringent model of experimental endocarditis due to Pseudomonas 
aeruginosa. 
 
1. From the standpoint of the bacterium:  
S. aureus in an important problem for human health and it can also produce different 
diseases in animals. This is particularly the case in Swiss dairy farms were a specific 
clonal complex is becoming epidemic in cowherds. These epidemic strains were found 
to belong to the Clonal Complex 8 (CC8), which is a typical human associated 
staphylococcal lineage. For this reason, these bovine-adapted strains were highly 
suspected to originate from human. The genetic makeup of collections of human and 
bovine CC8 strains was further compared using a comparative whole-genome 
sequencing approach in order to identify new factors that could correlate with the 
human to bovine jump. One of these factors could be a new SCC mobile element, 
called SCCbov, which was present in 38/39 of unrelated bovine CC8 isolates. 
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Interestingly, this SCCbov element, which was never found in human CC8 isolates, 
harbours a gene encoding a previously unknown LPXTG-protein (referred to as ADLB 
for Adherence-Like Bovine protein). The surface-attached nature of ADLB was 
confirmed by proteomic analysis of bovine CC8 S. aureus isolates as well as by cloning 
it and expressing it in Lactococcus lactis, followed by proteomic analysis, and by ELISA 
detection. Although present on the surface of recombinant lactococci, ADLB did not 
demonstrate adherence properties onto host matrix proteins such as collagen of 
fibronectin. Thus, it does not seem to be an adhesin. On the other hand, ADLB-positive 
lactococci adopted a striking star-like colony morphology on nutrient agar plates, 
confirming that there surface was altered. 
In order to acquire more insights in the function of ADLB, we performed a pull-down 
experiment using the ADLB recombinant L. lactis and whole protein extracts from 
bovine udder tissue. Interestingly, ADLB L. lactis bound dynein 1 heavy chain, a golgin 
like protein implicated in intracellular vesicle trafficking, as well as type I cytokeratin 
from the udder extract. Interaction with these proteins could possibly interfere with 
intracellular trafficking of endocsomal vesicles after bacterial internalization into bovine 
mammary cells, which could fit with the known intracellular lifestyle of S. aureus.  
In order to verify this hypothesis, two S. aureus CC8 bovine mutants were constructed 
and tested for internalization and survival in bovine mammary cell cultures (MAC-T cell 
line).  The first mutant was inactivated in the gene coding for the ADLB protein, but still 
carried the SCCbov element. The second mutant was cured from the SCC element in 
toto. The results showed that the two inactivated mutants were less able to escape 
endosomal vesicles after internalization. This could possibly highlight a key aspect of 
this protein in the pathogenesis of these strains.   
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Finally, human and bovine CC8 strains were analysed for possible differences in 
integrated prophages. Interestingly, all bovine strains could be categorized in three 
different subgroups regarding both gene microarray and prophage composition. The 
first group was composed of strains that contained one β-hemolysin-converting 
prophage and one lipase-converting prophage. The second group was composed of 
strains which had only the β-hemolysin converting bacteriophage and the third group 
was devoid of prophages. Interestingly, the first two groups clustered with mixt human 
and bovine strains, which was not the case of the third one that was composed only 
by bovine ones. This could suggests an evolutionary scenario where the human-to-
bovine jump necessitates first the acquisition of the SCCbov element, second the loss 
of the lipase-converting prophage, thus restoring lipase activity, and third the loss of 
the β-hemolysin-converting prophage, thus restoring the β-hemolysin function. In this 
scenario, SCCbov could provide staphylococci with advantages in cow colonization 
and virulence with the ADLB protein, restoration of lipase activity could provide a 
nutritional advantage in the milk-rich milieu, and restoring β-hemolysin could help 
colonize mammary epithelia, invade mammary cells or and/or escape professional 
macrophage attack. 
2. From the standpoint phages and prophages:  
In order to release their progeny, phages use phage-encoded lysins to lyse their host 
bacteria. However, the concurrent release of lysins in the milieu could be 
counterproductive in that it could unwillingly lyse neighbouring bacteria carrying 
prophage siblings, of lyse potential new bacterial preys. This is peculiarly true in Gram-
positive bacteria, which are devoid of an outer-membrane and can be lysed directly 
from the outside by soluble lysins.  
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Here we delved on the mechanism of action a new Streptococcus dysgalactiae phage 
lysin active that we described previously (Oechslin et al. Antimicrob. Agents 
Chemother. 2013; 57:6276-83). The lysin had an unusual multidomain architecture 
composed of one amidase (Ami) and one endopeptidase (CHAP) peptidoglycan-
hydrolase, as well as one cell-wall binding domain (CWBD). It was highly lytic against 
a large panel of streptococci and kept its antimicrobial activity in a mouse model of 
septicaemia.  
However, several fundamental questions remained open regarding the lysin’s 
architecture in the phage biology. For instance, what is the purpose of multi-
modularity? Indeed, precedents in the literature suggest that multi-modular lysins 
always carry one silent catalytic site. Is the putative silent domain an evolutionary by 
product on the way to be lost? How are the domains regulated in order to prevent 
untoward lysis of neighbouring bacteria?  
We first observed, by overexpressing each separate domains individually, that the 
amidase and CHAP domains synergized for lysing whole bacteria, in spite of the fact 
that CHAP alone was not active in term of bacterial lysis. However, optical and electron 
microscopy demonstrated that although CHAP did not lyse bacteria, it induced de-
chaining of streptococcal cell chains as well as detectable minimal alterations of the 
cell surfaces. Analysis of peptidoglycan degradation products by HPLC and LC-MS 
confirmed that all domains synergized for full enzymatic activity even though CHAP 
domain was not directly lytic. Peptide sequencing further highlighted that while the 
CHAP domain was able to resolve the stem peptides crosslinks from heptamers or 
tetramers to dimers, it was not able to resolve them to monomers, which is 
indispensable for total wall solubilisation. Indeed, dimers are enough to maintain a 
loose glycan-peptide meshwork that can prevent lysis.  
 15 
 
The CWBD was also studied by ELISA and diffusion essay and was shown not to 
confer bacterial species specificity, as usually presumed, but rather retained the lysin 
to the wall and wall debris. Hence, the CWBD had a dual action, promoting lysis on 
one hand and preventing extracellular diffusion of lysin on the other hand, thus 
protection neighbouring bacteria from untoward lysis. 
Finally, the PlySK1249 lysin was also observed to be proteolysed in a very specific 
manner in presence of cell wall protein extract or trypsin.   
3. From the standpoint of phage therapy:  
Phages can be implicated in key aspect of pathogenesis by introducing virulence 
factors or modulation their expression via type specific integration switch off/on as 
prophage. However, since these viruses are also notoriously known as bacterial 
predators, their use as an alternative to antibiotics has generated hope for the 
development of new antimicrobial strategies. Indeed, since the foundation of the 
modern antibiotic era by Ehrlich and Fleming in the beginning of the twentieth century, 
the overuse and misuse of antibiotics have been responsible for the constant selection 
of new antibiotic-resistant microorganisms. For this reason, new therapy and research 
in this field is needed. The use of bacteriophage as antibiotics, although not new, was 
recently revived in Europe with the European research and development project 
Phagoburn (http://www.phagoburn.eu). This study aimed at evaluating phage therapy 
for the treatment of burned patients using a cocktail composed of twelve different anti-
pseudomonas phages. 
In this third part of this thesis project, we aimed at evaluating the phage cocktail 
produced by the company Pherecydes Pharma for the Phagoburn clinical trial in a rat 
model of experimental endocarditis due to Pseudomonas aeruginosa. Although rare, 
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pseudomonas endocarditis is an archetype of highly lethal valve infection in human 
and thus a good model to test new therapies. We used both in vitro and in vivo models 
mimicking valve infection (fibrin clots and rats with catheter-induced aortic vegetations, 
respectively) to study the efficacy of an anti-pseudomonas Pherecydes Pharma phage 
cocktail and ciprofloxacin administered alone or in combination. In fibrin clots, the 
phage cocktail decreased bacterial density but regrowth due to phage resistance was 
observed after 24h. This regrowth could be prevented by the addition of ciprofloxacin. 
In rats, phage therapy alone decreased vegetation bacterial density as efficiently as 
ciprofloxacin, which is the gold standard for pseudomonas antibiotherapy. Moreover, 
combining phages with ciprofloxacin appeared highly synergistic. Phage-induced 
killing was also observed to correlate with in situ phage multiplication and cytokines 
production compared to antibiotherapy alone. The use of phage therapy also raised 
the question of the emergence of phage-resistant bacteria, as for antibiotics. 
Interestingly, we could detect phage resistant bacteria in vitro but not in vivo, which 
was most likely due to altered fitness. Indeed, phage-resistant clones isolated in vitro 
were significantly less infective than the phage-susceptible parent in rats with 
experimental endocarditis. This infectivity decrease correlated with modification of 
surface receptor that impaired either motility (in one mutant) or LPS production (in 
another mutant). These results were published (Oechclin et al. J. Infect. Dis. 2017; 
215:703-12) and demonstrated that phage therapy alone or combined with antibiotics 
represents a promising alternative in the treatment of severe P. aeruginosa infections 
and maybe more importantly that phage resistance might not a limitation of their use 
in therapy.  
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Conclusion and perspectives 
This thesis highlights a fascinating journey through horizontal interactions between life 
kingdoms. Originally interested in understanding the mechanisms of interaction 
between microbial surface components and the host, in the case of ADLB and the 
human-to-bovine host jump of S. aureus CC8, as well as phage lysin mechanisms of 
action and potential antimicrobial therapy, in the case of the multidomain phage lysin 
of S. dysgalactiae, it dragged us in much more fundamental questions regarding the 
comprehension of virus-bacteria-eukaryote interactions. 
For instance, the S. aureus jump from human to cows was associated with an array of 
factors. Although the ADLB surface protein appeared as central (no human strains 
possess it), it relied on parallel changes such as the loss of the lipase- and the β-
hemolysin-converting phages.  
This highlighted the central role of phage biology in the whole process, which was 
conceptually not new, but enriched knowledge on the system and provides now the 
tools to reconstruct the determinant steps of the host-jump by phage manipulation and 
in vitro reverse evolutionary experiments. Beyond academic interest, this could help 
track problematic germ evolution in cattle and the dairy industry. 
Likewise, studying the biology of phage lysins revealed a sophisticated intrinsic 
regulation aimed at protecting neighbouring bacterial cells, and thus preventing 
untoward bacterial lysis and abortion of potentially prophage siblings. This is different 
from the massive lysis and killing that is sought in the development of phage lysins as 
alternative anti Gram-positive therapy. Clearly, phage-bacteria co-evolution is more 
sophisticated than that. However, such understanding will be critical in designing 
efficient therapeutic lysins in R&D, for instance by taking into account the diffusion 
limiting action of the cell-wall binding domain. 
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Eventually, the translational experiments on phage therapy highlight the link between 
bacterial resistance to phages and the in vivo loss of bacterial fitness and infectivity. 
This of course does not solve the whole issue of phage resistance in therapy, as other 
resistance mechanisms than bacterial surface alterations do exist. But it provides hints 
toward alternative approaches in case of bacterial intracellular-related resistance 
mechanisms (e.g. restriction enzymes, CRISP), such as combination therapy or 
synthetic phage development.  
Thus, taken together, all three sets of experiments presented herein contribute to both 
fundamental mechanistic understanding and potential translational developments. 
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Chapter I 
 
Implication of mobile genetics element in the human-to-bovine host 
jump of Staphylococcus aureus clonal complex 8 
 
 
Myoviridae. Negative staining. 2016. F. Oechslin 
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Abstract 
Staphylococcus aureus isolates of human clonal complex 8 (CC8) recently emerged 
as a bovine mastitis pathogen. Studies suggested that human CC8 had adapted to 
cows and acquired of a novel staphylococcal chromosome cassette (SCCbov) carrying 
a novel LPXTG-surface protein gene named adlb, for Adhesin-Like Bovine protein. 
Here we confirm the human-to-bovine directional jump using whole-genome 
sequencing and core-gene comparison of 45 (8 human and 37 bovine) CC8 isolates. 
Moreover, we show that the jump was accompanied by sequential acquisition of 
SCCbov followed by successive losses of lipase- and β-hemolysin-converting 
prophages. 
SCCbov-mediated phenotype was studied using SCCbov excisants, adlb-inactivated 
mutants, and heterologous adlb-expression in Lactococcus lactis. ADLB was present 
on both bovine isolates and recombinant lactococci. It did not bind host matrix proteins 
or promote biofilm formation. However, when exposed to udder protein extracts, ADLB 
retrieved cytoplasmic molecules implicated in vesicle trafficking, including Dynein 1 
heavy chain, Golgin like protein and Keratin type I cytoskeletal protein. The role of 
ADLB in intracellular S. aureus trafficking was supported in mammary cell cultures. 
Parent strains were more prone than SCCbov or adlb mutants to escape endosomes 
and lyse host cells. Finally, we constructed isogenic bovine strains carrying SCCbov 
plus two prophages, one prophage or no prophages, allowing studying the host-jump 
in reverse evolution. 
Altogether, the present results highlight the MGE trafficking and some salient virulence 
mechanisms associated with the host-jump. Moreover, they suggest potential mastitis 
prevention strategies, such as vaccine blocking ADLB, and maybe lipase and β-
hemolysin, which are uniquely restored in bovine isolates. 
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Introduction 
Agriculture was developed around 11.500 years ago and is considered as the main 
factor that led to the Neolithic revolution. However, while agriculture was a source of 
food, it also generated unexpected problems including the transmission of zoonotic 
pathogens, which account for >60% of all known human virulent microorganisms 
including viruses, fungi, and bacteria [1]. One of these important bacteria is 
Staphylococcus aureus, which is an opportunistic pathogen for both humans and 
animals. In humans, the major reservoir of S. aureus is healthy carriers. They account 
for up to 30% of the population, and harbour the microorganism on their skin and 
mucosa, typically in the nose [2]. 
Although most healthy carriers never experience staphylococcal disease, S. aureus is 
the causative agent of a broad range of clinical syndromes extending from local 
disease to more severe systemic infections such as bacteremia, pneumonia or 
endocarditis [3]. It also has the capacity to acquire antibiotic resistance, as illustrated 
by methicillin-resistant S. aureus (referred to as MRSA). Currently S. aureus in general 
and MRSA in particular are among the most common causes of community- and 
hospital-acquired infections [4]. 
S. aureus carriage has also been reported in numerous animal species including dogs, 
cats, horses, pigs, and poultry [5]. It has become the most frequent etiological agent of 
bovine mastitis in modern farming. Bovine mastitis is an inflammation of the mammary 
glands that affects lactating cattle and is one of the main sources of economic loss for 
the dairy industry [6]. Infection starts by ascending colonization of the teat canal with 
bacteria coming from teat cup liners or milker’s hands or milking machines. After 
gaining access to the milk duct, bacteria adhere to the ductal and glandular epithelium 
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where they trigger macrophage and neutrophil migration and activation. This results in 
epithelial cell damage and in increased somatic cell counts (SCC) in the milk.      
However, while S. aureus is quite ubiquitous in terms of host species, different animals 
tend to harbour different lineages (i.e. clonal complexes, or CC for short). The evolution 
of S. aureus lineages is driven by genetic changes such as point mutations or 
importation of foreign DNA, which may confer novel phenotypic properties. The fittest 
mutants in specific conditions are privileged by the selective pressure of the 
environment, such as, for instance, host defences and antibiotics in humans and 
livestock.  
These genetic changes have a major impact on the architecture of the S. aureus 
genome, which is composed of three components: (i) a core genome with single 
nucleotide polymorphisms (SNPs), (ii) a variable core that changes according to 
lineages, and (iii) mobiles genetic elements (MGEs) that are acquired by horizontal 
gene transfer (reviewed in [7]). In S. aureus MGEs account for 10% to 20% of the 
genome. Moreover, individual MGEs can either be widely distributed among unrelated 
lineages, which suggests convergent selection stability, or poorly distributed with no 
sign of correlation with particular lineages, which suggests a seminal event responding 
to a new environmental pressure, or serendipitous evolutionary accident.  
Staphylococcal MGEs generally have a G+C content that is close to that of the host 
genome, suggesting that they were acquired by horizontal transfer from other 
staphylococci or related gram-positive bacteria, rather than from more remote 
organisms with different G+C contents, such as Proteobacteria. This permits escaping 
the restriction system that blocks DNA transfer between species. 
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Three main types of MGEs have been described so far in staphylococci, namely 
bacteriophages (phages), Pathogenicity Islands and staphylococcal cassette 
chromosome (SCC) [8]. Phages are between 20 and 40 Kb in size and are present as 
latent prophages integrated in the genome with short flanking inverted repeats (attL 
and attR) that match a short sequence at a specific insertion site of the chromosome 
(attP), and are recognized by an integrase, which triggers site specific integration. For 
example, β-hemolysin-converting phages have a specific insertion site in the gene 
coding for the β-hemolysin toxin, referred to as Hlb. Even if the lytic action of phages 
is potentially harmful, bacteria can take advantage of phages that carry virulence 
factors or toxin genes by inserting them as prophages and disseminate them via their 
own replication or via general transduction.  
S. aureus Pathogenicity Islands (SaPIs) are around 15Kb DNA sequences and depend 
on helper bacteriophages for their transfer. Like phages, SaPIs integrate into the 
genome at specific sites using integrases and provide the recipient with virulence 
factors such as toxins, super-antigens and immune suppressing factors [9].  
Like SaPIs, SCC mobile genetic elements are also discrete genetic sequences ranging 
in size from 3Kb to 60Kb. All SCCs have common elements including recombinase 
genes (ccrA/ccrB and / or C), a specific insertion site that is in the orfX gene, and 
flanking direct repeats for recombination. The mechanism by which SCC are 
transferred to different hosts is currently not elucidated, but could implicate general 
transduction. There are at least eleven described SCC types that convey resistance to 
methicillin (SCCmec), named Type I to XI. Ten of them carry the classic mecA gene 
(referred to as SCCmec) and one carrying the mecALGA251 variant (Type XI). The mecA 
gene confers resistance to methicillin and is associated with both healthcare- and 
community-acquired MRSA [10]. The mecALGA251 variant was originally described in 
 25 
 
livestock MRSA and was missed by molecular tests aimed at detecting mecA, because 
of its sequence variation [11]. MRSA positive for mecALGA251 were found in humans, 
but seem less implicated then mecA in large human epidemics of MRSA. 
The aptitude of S. aureus to infect different animal species, including humans, raises 
the question as to whether different strains are able to infect an array of different host 
species or whether they are rather adapted to a single host. Population genetics 
studies comparing bovine mastitis isolates to strains isolated from humans tend to 
indicate that mastitis is due to a small number of bovine-adapted S. aureus clones with 
lineages that are rarely found in human [12-17]. Although these studies suggest the 
existence of host range barriers, a small number of cross-species jumps have been 
documented including human to animal (anthroponotic switch), animal to human, and 
bidirectional jumps [18-21]. 
Interestingly, a previous study described that some bovine-adapted S. aureus strains 
showed a close genetic relationship to strains of the human clonal complex 8 (CC8) 
[22]. In this study, the genetic relatedness of 500 S. aureus mastitis isolates was 
compared to that of nasal carriage isolates from a population of farmers who were in 
direct contact with cows, as well as with carriage isolates from a population of non-
farmers healthy volunteers. Regarding the genotypic composition, farmers and non-
farmers were colonized by a variety of isolates that belonged to a series of shared 
CCs. In contrast, mastitis isolates were quite distinct from the human isolates, and 
particularly from the farmers’ isolates, in spite of close proximity with their cowherds. 
However, one-third of the bovine mastitis isolates belonged to the CC8 complex, which 
is typically associated with human infection and includes notoriously known strain 
USA300, which is the predominant clone responsible for community-associated MRSA 
 26 
 
in the United States of America [23]. The authors concluded on a possible host jump 
between human and cows with the emergence of new bovine adapted strains.  
A more recent study investigated the possible genetic determinants associated in this 
presumed host shift [24]. By using total chromosome microarrays, CC8 isolated in the 
previous study from cow mastitis were compared to typical bovine non-CC8 mastitis 
isolates as well as to CC8 isolated from colonized or infected human patients. 
Clustering analysis revealed three CC8 subgroups, named Ia, Ib and Ic, respectively. 
Two of these subgroups (Ia and Ib) contained a mix of human and bovine strains, 
whereas the third subgroup (Ic) contained only bovine isolates. Strikingly, irrespective 
to the three subgroups, all bovine strains harboured a non-mecA SCC element 
(referred to as SCCbov in the following), which carried a gene coding for a LPXTG 
surface-like protein. In addition, the bovine-only subgroup (Ic) had lost the β-hemolysin 
converting prophage. 
In parallel, veterinary epidemiologic studies revealed a peculiarly invasive bovine 
mastitis clone referred to as genotype B (GTB) based on 16S-23S ribosomal spacer 
PCR-typing [25]. Moreover, recent genomic analyses indicated bovine mastitis clone 
GTB was similar to human complex CC8 [26]. Finally, the GTB (or bovine CC8) strains 
also contained a gene encoding unique new LPXTG surface protein that was similar 
to the LPXTG described above [24] and was tentatively named adlb, for “Adhesin-Like 
Bovine” protein [27]. Thus, veterinary epidemiologic studies converged to the same 
host-jump conclusion than human studies regarding to CC8 S. aureus [22] [24]. 
In this present project we aimed at both confirming the presumed adaptation direction 
from human-to-bovine host, and understanding the molecular and pathogenic 
mechanisms behind it. To this end, robust phylogeny analysis based on core genome 
genes was combined to molecular biology. Beyond genetic and molecular mechanistic 
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comprehension, the ultimate goal was to construct the system for testing a “reverse 
like” evolution model, by adding or removing the genetic determinants that are 
supposed to be relevant for host adaptation (i.e. prophages, SCC, and the hypothetical 
surface protein). The different strains were then tested and compared for infectivity 
regarding internalization on bovine cell cultured epithelium. 
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Materials and methods  
Bacterial strains, media and growth conditions. Bacterial strains and plasmids 
used in this study are listed in supplementary Table 1. Escherichia coli was cultivated 
in Luria-Bertani (LB) medium (Becton Dickinson, Sparks, MD) supplemented with 100 
mg/L ampicillin (AppliChem, Darmstadt, Germany) at 37°C. S. aureus strains were 
grown with aeration in trypticase soy broth (TSB) (Difco Laboratories, Detroit, MI) at 
180 rpm 37°C. If required, tetracycline and erythromycin (AppliChem) were added at a 
final concentration of 10 mg/L for plasmid propagation and 5 mg/L for flow cytometry 
analysis. Oxacillin was commercially purchased and used at the sub-MIC 
concentration of 4 mg/L for methicillin-resistant staphylococci. Mitomycin C (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) was used at a final concentration of 1 
mg/L. 
 
PCR and DNA manipulations. For polymerase chain reaction (PCR) GoTaq DNA 
polymerase (Promega Corp.) was used for colony PCR screening analysis. KAPA HiFi 
DNA Polymerase (KAPA Biosystems, Cape Town, South Africa) was used to amplify 
fragments required for cloning. All reactions were carried out according to 
manufacturers’ specifications. The primers used in this study are listed in 
supplementary Table 1. For S. aureus, genomic DNA was extracted using a protocol 
described previously in [28]. For E. coli, plasmids were isolated using the QIAprep Spin 
Miniprep Kit (QIAGEN, Hilden, Germany). For S. aureus, an additional lysostaphin 
treatment (final concentration 0.5 µg/ml) was performed before the lysis step. 
Digestions with restriction enzymes (Promega Corp.) were carried out according to the 
manufacturer’s specifications. PCR fragments were purified using the “QIAquick PCR 
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Purification Kit” (Qiagen Inc.) and gel bands were purified using “QIAquick Gel 
Extraction Kit” (Qiagen Inc.) according to manufacturer’s protocols. Ligations were 
performed using 1 µl of T4 ligase (Promega Corp.) according to the manufacturer’s 
specifications. 
 
Genome sequencing, assembly and annotation. Genomic DNA from 45 S. aureus 
CC8 strains (37 bovine strains and 8 human strains, listed in table 1) was purified using 
the Wizard Genomic DNA purification kit (Promega, Dübendorf, Switzerland). Genomic 
DNA libraries were prepared using 1μg of the purified genomic DNA and the TruSeq 
DNA LT Sample Preparation Kit according to the manufacturer’s protocol (Illumina, 
San Diego, USA; Cat. No. FC-121-2001). The resulting libraries were pooled into a 
single library for 2x100-bp paired-end sequencing on the Illumina HiSeq 2500 
sequencer using TruSeq PE Cluster Kit v3 (Cat. No. PE-401-3001) and TruSeq SBS 
Kit v3 (Cat. No. FC-401-3001). Data were processed using the Illumina Pipeline 
Software package v1.82 and aligned using Eland v2e. Assembly of paired-end reads 
was done with Edena [29]. Contigs were submitted to RAST v 2.0 for automated 
annotation [30]. The full genome sequence of Staphylococcus epidermidis strain ATCC 
12228 was obtained from NCBI (Accession N°: NC_004461.1) 
 
Phylogenetic analysis. Fasta files of Open Reading Frames (ORFs) (both nucleotide 
and amino-acids sequences) from each genome were downloaded from RAST and 
used by two in-house perl scripts (available upon request) to build a phylogenetic tree. 
Briefly, core proteins, i.e. proteins encoded on the genome of the S. aureus strains and 
S. epidermidis ATCC 12228 were identified by blasting each single protein sequence 
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of a given strain to each single protein sequence of the other strains using BlastP with 
e-value threshold of 10−10. Corresponding nucleotide sequences of genes coding for 
core proteins present in single copies in all genomes were further used to build a 
multiple alignment with MAFFT-7.187 [31]. Newick formula was obtained by submitting 
the MAFFT output file to FastTree-2.1.7 [32]. Finally, the Newick formula was uploaded 
in Njplot 2.3 [33] to visualize and root the corresponding phylogenetic tree using S. 
epidermidis ATCC 12228 as outgroup. 
 
Heterologous expression of the new LPXTG (ADLB) protein in Lactococcus 
lactis. The gene (tentatively named adlb) coding for the LPXTG (ADLB) protein 
present in the SCCbov cassette of S. aureus strain M186 was cloned in the expression 
vector pORI23 (generating pORI23-ADLBM186) in L. lactis following the system 
described in [34]. Briefly, the surface protein was PCR amplified using the sets of 
primer ADLB_SalI and ADLB_PstI and digested with their respective enzyme to be 
finally cloned in the pORI23 shuttle vector. After E. coli amplification and sequencing, 
the plasmid was finally transformed in L. lactis by electroporation. ADLB-expression 
was confirmed by western blotting and liquid-chromatography coupled to mass 
spectrometry (LC-MS), as described below. In addition, a mutated version of the ADLB 
protein was also produced by replacing the LPXTG signal of the protein by a 6-his-tag. 
The his-tag substitution was done by PCR amplification of the plasmid pORI23-
ADLBM186 using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, 
Massachusetts, USA) and the set of primers Q5SDM_ADLB_F and Q5SDM_ADLB_R. 
The reaction product was then transformed into E. coli for amplification and sequencing 
and finally transformed in L. lactis as described before.   
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Surface protein analysis using western blotting, ELISA and LC-MS. Cell-wall 
associated proteins were extracted from L. lactis and S. aureus as described in [34]. 
Western blotting was performed as described before [35] and blots were incubated 1 
h with a 1:1000 dilution of anti-ADLB antibody following by a 1 h incubation with a 
1:2000 dilution of peroxidase-conjugated goat anti-rabbit secondary antibody. Bands 
were detected using ECL Western blotting detection reagent (Amersham Bioscience. 
Piscataway, NJ). The presence of the ADLB protein on the recombinant L. lactis was 
also tested by ELISA on overnight cultures or directly on colonies. To this end, 
overnight cultures were washed three-time with PBS and colonies were picked and 
directly resuspended in 500 µl of PBS. 100 µl of cell solution was then incubated in a 
96 well plate for 1h at 37°C. After three PBS washes, the plate was blocked for 1 h 
with a solution of PBS-3%BSA.  After a second three-time PBS wash, anti-ADLB 
antibodies were added at a dilution of 1/1000 and incubated for 1 h. After a third three 
time PBS wash, the plate was incubated 1h with a 1:2000 dilution of peroxidase-
conjugated goat anti-rabbit secondary antibody. 150 µl of colorimetric substrate (TMB, 
Thermo Fisher Scientific, Massachusetts, USA) was added to the plate after six PBS 
washes. 150 ul of 2M H2SO4 was added after 30 min of incubation to stop the reaction 
and absorbance was recorded at 450nm. The anti-ADLB was composed of an 
equimolar mix of two antibodies raised against two fragment of the protein 
corresponding to the amino acid position 73-87 and 602-616 (Eurogentec, Liège, 
Belgium).  
For LC-MS analysis, cultures were adjust to 1x109 CFU/ml in PBS and digested with 1 
ug/ml trypsin (Promega Corp) for 1 hr at 37 ºC. The suspension was centrifuged, the 
supernatant filtered, and then dried ON in a speedvac. Samples were suspended in 
100 mM ammonium bicarbonate, pH 8.5 (Sigma), to which 1,4-dithio-DL-threitol 
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(Fluka) was added to a final concentration of 4.5 mM and incubated 30 min at 60 ºC 
with shaking. After cooling, iodoacteamid was added to a concentration of 10 mM and 
samples were incubated 30 min at RT in the dark. A second digestion with trypsin was 
performed ON at 37 ºC. Samples were cleaned with Sep-Pak tC18 cartridges (Waters). 
LC_MS was performed at the protein analysis facility of the University of Lausanne 
(PAF, Center for Integrative genomic, University of Lausanne, Switzerland) 
 
FACS analysis. For flow cytometry, cells were grown to OD 0.4 and kept on ice. 1 ml 
samples were then washed three time with ice cold PBS and transferred to a 5 ml 
Falcon tube. Flow cytometry was performed with a FACS-Aria (BD Biosciences, 
Erembodegem, Belgium). GFP fluorescence was recorded in the FL1 (525+15 nm 
channel). Cells were immediately plated on blood agar after sorting. 
 
Excision of the SCCbov cassette and inactivation of the adlb (LPXTG-protein) 
gene in prototypic bovine strain M186. In order to study the phenotype conferred by 
the SCCbov cassette and the new ADLB surface protein in bovine CC8 staphylococci, 
it pas critical to generate isogenic mutants lacking these particular determinants. 
Prototype bovine strain M186, belonging to subgroup Ib, was used to this end. 
First, to screen for spontaneous SSCbov excisants, bovine strain M186 was 
transformed with plasmid pPGFP, which expresses GPF under the promoter of the 
SCC recombinases ccrA/ccrB [28]. GFP-overexpressing cells were retrieved by FACS-
sorting, grown into colonies, and screened for the loss of SCCbov by PCR. Loss of 
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SCCbov was confirmed by the concomitant loss of the surface ADLB protein western 
blot and by LC-MS.os  
Second, bovine M186 mutants inactivated in adlb (M186 Ω adlbM186) were generated 
using the TargeTron Gene Knockout System (Merck). This system is based on the 
activity of group II introns, which can insert themselves into a user-specified 
chromosomal gene via the activity of an RNA-protein complex (RNP) expressed from 
a single plasmid (pNL9164) [36]. First, the RNA portion of the RNP was mutated to re-
target insertion into the desired gene. To do that, a computer algorithm 
(http://www.sigmaaldrich.com/life-science/functional-genomics-and-
rnai/targetron.html) was used to identify group II intron target sites in the adlb gene. 
Among the primer sets that were output from the algorithm, the one comprising primers 
IBS, IBS1d and IBS2 was used to synthesize the DNA coding for the mutated intron 
RNA by PCR using pNL9164 (containing the RNA portion designed to target the hsa 
gene) as a template. The resulting 350 bp PCR product was then digested with HindIII 
and BsrGI and ligated into pNL9164, also digested with the same enzymes. The 
ligation reaction was transformed into E. coli DH5α cells. The presence of the RNA 
portion mutated to target the adlb gene was confirmed by sequencing. The construct 
was then electroporated into the S. aureus RN4220 restriction-defective strain and 
then in the S. aureus M186 cells. To induce the TargeTron system, cells were grown 
at 32°C in BHI medium containing 10 µg/ml erythromycin to the exponentially phase 
(OD = 0.5) and then induced with 10 µM CdSO4 for 90 min. Cells were then plated on 
BHI plates containing 10 µg/ml erythromycin and incubated ON at 32°C. The day after 
colony PCRs were performed to screen for the presence of the intron within the adlb 
gene, using primers adlb_fw and Fw4200_adlb (supplementary Table 1). Colonies 
containing the adlb wild type gene generated a product of 2.246 Kp, whereas colonies 
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carrying Ωadlb generated a PCR product of approximate size of 3.3 Kb. The presence 
of the group II intron therein was verified by sequencing. 
 
Pulling downs proteins from udder extracts using ADLB-expressing L. Lactis. 
Fresh udder tissues from lactating cows were obtained from the slaughterhouse, 
dissected and glandular tissues were grinded with a mortar-pistil after being frozen in 
liquid nitrogen. Homogenized tissues were then suspended in T-PER® Tissue Protein 
Extraction Reagent (Thermo Fisher Scientific, Massachusetts, USA) at 1g / 20 ml 
according the manufacturer’s instructions. Protein extracts were dialyzed overnight 
(12-14 kDa membrane tubing, Spectra/Por®, Rancho Dominguez, CA, USA) at 4°C 
against PBS and then incubated for 1 h with either the parent L. lactis, L. lactis carrying 
the empty pORI2 vector, or L. lactis / pORI23-ADLBM186, washed three time with PBS 
and processed for surface proteomics as described before. The same experiment was 
done with PBS instead of protein extracts as a negative control. 
 
Adherence test and biofilm essay. Adherence to solid-phase human and bovine 
collagen and fibronectin (Sigma-Aldrich, Munich, Germany) using ADLB-expressing L. 
Lactis, M186 Δ SCC_bov and M186 Ω ADLB was measured a previously described 
[37]. Biofilm formation was tested as in [38]. 
 
Prophage excision and re-introduction. Prophage excision was done by UV 
induction as described in [7]. Briefly, 25 ml exponential phase cultures were washed 
one time with ice-cold NaCl and 12.5 ml was transferred in empty petri dishes. UV 
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induction was done for a total dose of 900 erg/mm/min. To screen for bacteria that had 
lost the β-hemolysin-converting prophage, irradiated cells were serially diluted, plated 
on blood agar, and screened colonies that had a restored hemolytic phenotype. The 
same protocol was used for bacteria that had lost the lipase-converting phage, except 
that irradiated bacteria were platted on TSB agar containing 2% tributyrin and screened 
was for colonies that had restored a clear halo around them. Excision was confirmed 
using the set of primers hlb-2 and hlb-527 (supplementary table 1) to generate a 526 
bp fragment when excised from the genome. 
In order to integrate prophages into the different S. aureus strains, prophage-excision 
was first induced by adding mitomycin C (1µg/ml) to exponentially growing culture (OD 
= 0.4). After ON incubation, cultures were centrifuged and the supernatant filtered 
through a 200 nm pore filter. Hundred microliter aliquots were then serially diluted and 
mixed with 4 ml of soft agar contain 200 µl overnight culture of the prophage recipient 
strain and incubated at 37°C for 24 h. Lytic plates were isolated by puncturing them 
with a micropipette tips and re-suspended in saline solution for serial dilution on blood 
agar plate. Integration was observed by phenotypic conversion and confirmed by 
multiplex PCR using the set of primers lip2_Fw, 366_Rv and int_Rv (supplementary 
Table 1).  
 
Cell culture and bacterial internalization assay. MAC-T cells (kindely provided by 
Madame Olga Wellnitz, University of Bern, Switzerland) were cultured in growth 
medium consisting of Dulbecco’s modified Eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), penicillin and streptomycin (100 units penicillin and 0.1 
mg streptomycin/mL final concentration, Sigma-Aldrich), and ITS liquid media 
supplement (Sigma-Aldrich). Cells were cryopreserved in DMEM / F12 (Sigma-Aldrich, 
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Munich, Germany) containing 20% FBS and 10% dimethyl sulfoxide (DMSO, Sigma-
Aldrich), and stored in liquid nitrogen. For bacterial internalization test, cells were 
grown in BD FalconTM 6-well cell culture plates (BD Biosciences, San Jose, CA, USA) 
at 37°C and c.a.16 h prior to infection the culture medium was replaced by fresh 
medium without antibiotics. For infection, bacteria from ON cultures were washed 3 
times with PBS, and re-suspended at various concentrations in culture medium without 
antibiotics before 1 ml aliquots were added to the cell culture wells. After 2 h of 
incubation, plates were washed and the antibiotic-free culture medium was replaced 
with fresh medium containing 100 mg of gentamicin. After different incubation periods 
the cell monolayers were examined by optical microscopy for visible cell damages, 
before being washed 3 times with sterile PBS and lysed by adding 1 ml of distilled 
water supplemented with 0.24% trypsin and 0.025% triton X. Cell lysates were serially 
diluted and plated for viable counts to quantify intracellular bacteria.    
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Results 
Human and Bovine CC8 phylogeny based on core genome analysis. In order to 
determine the direction of host jump shift between human and bovine CC8 strains, a 
phylogeny study based on whole genome analysis was undertaken using a collection 
of 45 (8 human and 37 bovines) S. aureus CC8 independent isolates. This core 
genome is composed of ca. 2100 genes that are present in all 45 strains. After total 
genome sequencing by Illumina, genes present in the core were extracted and aligned 
using MAFFT. The output was analyzed by RAXML for the creation of a phylogenic 
tree. The tree (presented in Figure 1) shows that all the CC8 bovine isolates clustered 
together in a branch emerging from human strains, with the exception of SaMBk and 
SaMBc. This suggests that, at a certain point, one or more successful events of host 
adaptation have happened and led to a clonal spread of bovine-adapted CC8 strains. 
Interestingly, we could confirm that all the bovine strains present in the cluster harbored 
the non-mecA SCCbov element carrying the gene of a predicted new LPXTG surface 
protein (originally name orf1 and recently renamed adlb) [24, 27], as well as the 
conserved ccrA/ccrB recombinases of SCCmec. Alignment of the SCCbov sequences 
present in the different strains did not highlight any differences regarding gene 
composition and synteny (result not shown). In addition, the SCCbov element was 
absent from the two bovine isolates SaMBk and SaMBc, which did not cluster with the 
rest of the bovine strains (Figure 1). These two isolates differed from the bovine cluster 
in several respects. First, strain SaMBk did not carry the SCCbov elements inserted at 
the OrfX location. Second strain SaMBc carried a type IV SCCmec cassette instead of 
SCCbov at this very location, and appeared to be a descendant of the human MRSA 
SaI2. Third they did not give raise to a bovine cluster similar to that of the SCCbov 
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containing strains. Thus, they were likely to represent accidental passage or accidental 
contamination rather than established bovine strains.  
Regarding the prophage content of the different strains, three main observations could 
be made. First, the β-hemolysin-converting prophage was present in all human strains. 
This was however not the case for the bovine strains, as it was absent in 1/3 of the 
isolates. Second, the lipase converting phage was present in both types of isolates but 
was less represented than the β-hemolysin-converting one. Third, prophages were 
also observed to be integrated in other position in human strains but not in the bovine 
ones were c.a. half of the strains did not had prophages at all. Interestingly, strains 
having lost their prophage content tend to cluster well, like for example for M192, M160, 
M86, M283, MFU1. This was less the case for the spa-typing were micro clusters could 
still be observed.   
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Figure. 1. A) Phylogeny of the 45 CC8 strains (8 of human and 37 of bovine origin) based on the core 
genome, which account for c.a. 2100 genes present in all 45 CC8 strains. Bovine strains are indicated 
by asterisks and SaI stands for strains isolated from infected patients, SaLaus for strains isolated from 
healthy carriers and SaM for strains isolated from bovine mastitis. The scale bar represents 10-5 
mutations. The branch corresponding to the S. epidermidis ATCC 12228 outgroup was removed for 
convenience. B) The right side panel indicates the presence (green) or absence (red) of the SCCbov 
element, the lipase-converting prophage (lipase conv. Φ), the β-hemolysin-converting prophage (β-
hemo. Conv. Φ) and other integrated prophage. In addition, the spa-type of the different strain is 
indicated.  
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Excision of the non-mecA SCCbov mobile element and inactivation the novel 
adlb surface protein gene. The results obtained with the phylogeny analysis revealed 
the possible importance of the non-mecA SCCbov element in the host jump. In order 
to study its implication in virulence, prototypic bovine strain M186 was used to both 
excise the SCCbov cassette in toto (referred to as M186 ∆ SCCbovM186 in the 
following), and to interrupt its ADLB-encoding gene. 
Excision of the SCCbov cassette was first attempted by the strategy developed by 
Katayama et al [39], consisting in transforming M186 with the plasmid pSR3-1 that 
constitutively expresses the ccrA and ccrB recombinases present in the type II 
SCCmec of MRSA N315. Recombinase overexpression was meant to promote 
SCCbov excision. Transformed cells were then screened of excisants by PCR. 
Although the SCCmec and SCCbovM186 shared the same attB and attL flanking region 
and the same ccrA and ccrB recombinases (with 99% coverage and 95% homology 
taking minus 200bp from start into account), no SCCbov excisants could be isolated 
using this method.  
To achieve excision, we developed an alternative method, using flow cytometry to 
enrich in cells spontaneously expressing the ccrA/ccrB recombinases. To this end, 
strain M186 was transformed with the plasmid pPGFP-N315 [28], which expresses 
GFP under the control of the ccrA/ccrB promoter (Figure 2.A-D). Flow cytometry 
indicated that the proportion of cells spontaneously activating the ccrA/ccrB promoter 
was between 3% and 5%, which was comparable to the rate of spontaneous 
expression of ccrA/ccrB observed with MRSA N315 [28]. The population expressing 
GFP was then sorted and DNA from colonies was extracted and further analyzed by 
PCR (Figure 2.E). We observed that SCCbov had been excised in up to 50% of 40 
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randomly screened colonies. One colony was picked, purified and named M186 Δ 
SCCM186 for further analyses.  
 
 
Figure. 2. Flow cytometry analysis of strain S. aureus N315 (A) and M186 (B) transformed with plasmid 
pPGFP-N315 expressing GFP under the control of the ccrA/ccrB promoter. Both strains showed similar 
levels of GFP expression in the population (c.a. 3 to 5 %). For each measurement, the subpopulation 
expressing GFP was determined with respect to negative (C) (strain N315 with an empty plasmid) and 
positive controls (D) (strain N315 with GPF under constitutive expression) as described by Stojanov et 
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al. and who made de pPGFP plasmid and control strains [28]. (E) Upper part: locations of the PCR 
primers allowing detecting the presence or the loss of the SCCbov cassette. Lower part:  PCR products 
from the SCCbov-positive parent M186 (left part of the gel) and a SCCbov-excisant, named M186 Δ 
SCCbovM186 (right part of the gel) as indicated by the absence of amplification via primer sets 1-2 and 
3-4 (as in the SCCbov-positive parent) and amplification via primer set 1-4.   
 
 
In addition, an ADLB-defective mutant (M186 Ω ADLB) was produced by site-specific 
transposon insertion using the TargeTron gene knockout system (see supplementary 
Figure 1). 
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Expression and characterization of the new ADLB surface protein in bovine S. 
aureus and recombinant L. lactis. The SCCbov element, which was present in all 
the bovine strains, unanimously carried a gene with all the characteristics of a surface 
protein (Figure 3.A). Originally named LPXTG-BovM186, in reference to the C-terminal 
LPXTG sequence and the bovine S. aureus M186 in which it was observed, it was 
recently renamed ADLB, owing to its presence in all observed bovine CC8 isolates and 
its apparent resemblance to surface adhesins [27].  
To confirm the presence of the ADLB protein on the surface of the bovine strain M186, 
intact bacteria were incubated with trypsin to cleave surface proteins. Figure 3.B shows 
that the expected ADLB peptides were released from the bacterial surface and 
detected by LC-MS analysis. Thus, ADLB was indeed present and well represented 
on the surface of the bacteria.  
In a parallel experiments, we constructed L. lactis expressing ADLB heterogeneously 
through the expression plasmid pORI23-ADLBM186. As a control, we also contructed a 
version of the ADLB protein in which the LPXTG domain was replaced with a 6-his-tag 
(pORI23-ADLBM186 ∆ LPXTG). As for S. aureus M186, pORI23-ADLBM186 recombinant 
L. lactis expressed surface ADLB, which was detected by LC-MS (see Supplementary 
Figure 2). Moreover, the presence of ADLB on the surface of S. aureus M186 and 
recombinant lactococci was further confirmed by western blotting, using cell wall 
protein extracts and antibodies directed against two epitopes present in the N-terminal 
part or in the C-terminal G5 domain (Figure 3.B, lane 4). 
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Figure 3. Detection of ADLBM186 on bacterial surfaces by LC-MS. (A) Structure of the putative surface 
protein present in the SCCbovM186 element named hereafter ADLBM186. The protein possesses an N-
terminal signal motif for secretion followed by 5 repeats of 16 amino acids. The C-terminal cell-wall 
sorting signal LPXTG motif is also present after a proline-glycine rich region that is composed of 25 
PEQPGN repeats. The only partial homology obtained for the protein was for the B-repeat region that 
matched G5 like domains. Bacterial surface peptide digest of ADLBM186 confirmed its presence on the 
surface of strain M186. Amino acid sequences of the protein that matched with the peptides analyzed 
by LC-MS are highlighted in yellow. Methylated amino acids are highlighted in green. (B) The presence 
of ADLBM186 was also assessed by western blot on the surface and in the supernatant of L. lactis / 
pORI23 (lane 1), L. lactis / pORI23-ADLBM186 (lane 2), L. lactis / pORI23-ADLBM186 Δ LPXTG (lane 3), 
and S. aureus M186 (lane 4). 
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Size variations of adlb and its ADLB protein product in bovine CC8 S. aureus. 
The adlb gene was not only present and expressed in prototype strain M186, but also 
in all the other bovine adapted strains studied herein, with size variations ranging from 
c.a. 3.5 Kb to 6.5 Kb (Supplementary Figure 3.A). Size variations could not be directly 
localized by genomic sequencing since problems of missassemblies were always 
present in this specific gene. Therefore, the exact sequence of the adlbM186 gene was 
obtained by PCR walking and by adding DMSO to the reaction mixture, which is known 
to destabilize DNA secondary structures. By using PCR amplification directed on the 
repeat regions, size variation was observed to be located in specific region 
(Supplementary Figure 3.B). 
Different CC8 strains showing adlb size variations were also analyzed by western blot 
(Supplementary Figure 4). In addition, we included the CC8 strain MBk that does not 
carry the SCCbov element harboring the ADLB protein gene. According to these 
results, the ADLB protein was present on the cell wall of all the CC8 bovine strains. 
Moreover, the variation in size of the adlb gene also correlated with the size of the 
proteins. On the other hand, the protein was absent for the SCCbov-negative strain 
MBk, used as a control.  
Of note, in S. aureus extracts the ADLB protein generated several bands of different 
sizes. This suggests that the protein might be processed, as has been described for 
SasG [38] (see also Supplementary Figure 5). The pattern was also strain dependent 
and a correlation was observed between the number of bands and the size of the gene 
observed (Supplementary Figure 3.A et 4). On the other hand, ADLB was not 
processed when expressed in the L. lactis background (Figure 3.B). 
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Seeking a function for the ADLBM186 surface protein. Protein sequence analysis 
using InterPro could not predict any protein family membership, biological process or 
molecular function for this new surface protein. Searches using BLAST or HMMER 
showed homology with accumulation associated proteins for specific sites including 
the signal peptide, sorting signal and B repeats that matched with G5 domains (see 
also Supplementary Figure 5) [40].  
In order to study the potential phenotype conferred by ADLB, we first used the 
recombinant L. lactis / pORI23-ADLBM186, which expressed ADLB out of the potentially 
redundant S. aureus surface protein background (line 3 in Figure 3.B). Strikingly, 
Lactococcal colonies produced star-like irregular colonies when grown on blood agar 
(Figure 4 A). The phenotype was correlated with the presence of the protein by using 
ELISA directly on the colonies (Figure 4. B).  
 
 
Figure 4. (A) Phenotypes observed for the L. lactis / pORI23-ADLBM186 after growth on antibiotic free 
blood agar. A certain number of colonies were growing with an irregular shape. (B) By using ELISA 
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directly on the colonies, the irregular shape phenotype was correlated with the presence of the ADLBM186 
on the surface of the recombinant L. lactis. 109 log/ml of cultured bacteria was used as control.  
 
However, no adherence-promoting activity to host matrix proteins (bovine collagen and 
bovine fibronectin) or milk was observed (results not shown) with lactococci. Moreover, 
we used the parent strain M186 and its M186 Ω adlb to test biofilm formation. Here 
again, no difference between the parent and the mutant was found. Thus ADLB might 
have a different function. 
Finally, in order to gain more information on the potential function of the ADLB protein 
we performed a pull down assay using the L. lactis / pORI23-ADLBM186 recombinant 
and protein extracts from fresh udders of milking cows. Recombinant lactococci were 
incubated with the udder protein extracts, recovered by centrifugation, washed 3 times, 
and lactococcal surface proteomics was performed as described above. Negative 
controls included the L. lactis / pORI23 strain carrying an empty vector and the two test 
lactococcal strains incubated without udder extracts. Potential protein candidates were 
the ones observed only in the L. lactis / pORI23-ADLBM186 and absent in the negative 
controls (see Table 1). Interestingly, out of 9 proteins that were only recovered on the 
surface of the recombinant L. lactis, three could be involved in eukaryote intracellular 
vesicle trafficking, including Golgin like protein, a Dynein 1 heavy chain, and a Keratin 
type I cytoskeletal protein. Hence, ADLB could be involved in the intracellular 
staphylococcal lifestyle. 
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Identified Proteins 
Molecular 
Weight 
Fold Change 
(8416/8417) 
L. lactis / 
pORI23-
ADLBM186
+ extract 
L. lactis / 
pORI23 + 
extract 
L. lactis / 
pORI23-
ADLBM186 
L. lactis / 
pORI23 
ADLBM186 125 kDa 33.0 36 0 39 0 
Golgin like protein 378 kDa 7.4 8 0 0 0 
Dynein 1 heavy chain 532 kDa 4.6 5 0 0 0 
Galactokinase  42 kDa 4.6 5 0 0 0 
Alpha-enolase  47 kDa 4.6 5 0 0 0 
Poly(rC)-binding protein  37 kDa 4.6 5 0 0 0 
D-3-phosphoglycerate 
dehydrogenase  56 kDa 4.6 5 0 0 0 
flavoprotein subunit beta  28 kDa 4.6 5 0 0 0 
Keratin, type I 
cytoskeletal  49 kDa 1.0 4 0 0 0 
 
Table 1. Proteins pulled down from udder extracts by L. lactis / pORI23-ADLBM186 
 
 
Cell culture internalization tests using MAC-T cell lines. As shown with the pull-
down experiment, the ADLBM186 could potentially interact with proteins implicated in 
vesicle trafficking. Since internalization and phagosome escape is an important step in 
staphylococcal cell invasion, we tested this hypothesis using an internalization essay. 
To this end, a monolayer of MAC-T bovine mammary epithelial cell line was infected 
first by the M186 Ω ADLBM186 and then by M186 Δ SCCbovM186 to observe any 
difference in intracellular survival and cell morphology compared to the M186 wild type. 
Interestingly, excision of the SCCbov element or knockout of the adlb gene did not 
affect cell internalization at first. However, after engulfment the parent M186 strain 
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readily escaped endosomes and lysed the mammary cells. This resulted in a 
disintegration of the host cells and a decrease in bacterial viability (> 2 log CFU after 
24 h) due to their release in the gentamicin-containing medium (Figure 5.A). In 
contrast, excising the SCCbov cassette or knocking out the adlb gene resulted in more 
prolonged endosomal sequestration and increased intracellular survival. Indeed, the 
two knockout strains were observed in vesicles, which was not the case for the WT 
(Figure 5.B). Since mammary cells are not professional macrophages, they are not 
expected to readily kill bacteria after engulfment. 
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Figure 5. Cell culture internalization tests using MAC-T cell line. (A) Cells were infected by the M186 or 
M186 Ω ADLBM186 and M186 Δ SCCbovM186 at an initial inoculum of 107 CFU/ml. After different 
incubation time points, cell were washed, lysed and plated. (B) Light microscopy after 24h incubation of 
M186 or and M186 Δ SCCbovM18 strains.  
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Prophage content of human and bovine CC8 isolates. The genomes of the different 
human and bovine strains were also analyzed using the PHAge Search Tool (PHAST) 
in order to search for integrated prophages (Figure 7.A and 7.D). Based on phage 
content, we found that all isolates tended to cluster in three subgroups, which were 
similar to the three subgroups observed using microchips (Figure 6) [24]. 
 
 
 
 
Figure 6. Microarray-based clustering of human and bovine CC8 isolates adapted from [24]. This 
clustering was confirmed by core genome gene phylogeny (Figure 1) and further associated to prophage 
content (see text for details). Bovine isolates are indicated in bold.  
 
Interestingly, strains of mixed human-bovine subgroup Ia were observed to have two 
intact predicted prophages, one β-hemolysin converting prophage and one lipase 
converting prophage, respectively. Moreover, all strains from mixed human-bovine 
subgroup Ib had lost the lipase converting prophage but still contained the β-hemolysin 
converting prophage, whereas the strains of the bovine-only subgroup Ic were devoid 
of integrated prophages. Thus, in addition to the acquisition of SCCbov, which was 
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always present in bovine isolates, the loss of specific prophages seemed also to 
accompany the human-to-bovine host jump. 
In addition, we also observed that bovine CC8 strains shared a similar GC content, 
with the same cumulative GC skew curve (supplementary Figure 6 A). An inversion in 
the cumulative GC skew between c.a. 993 and 995 kbp was present in all strains and 
corresponded to the integration site of an incomplete prophage (supplementary Figure 
6 B). The other intact prophages had a GC content similar to the S. aureus genome, 
which suggests horizontal transfer. 
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Figure 7. Analyses of prophages present in prototypic CC8 strains from subgroups Ia, Ib and I.c using 
PHAST (PHAge Search Tool). (A) Two prophages annotated as intact (red squares) were present in the 
strain M124, M20 and M37 (only M124 is shown in the Figure) that are part of the mixed human-bovine 
group Ia. The prophage present at c.a. 2m bps is a β-hemolysin converting bacteriophage, which is also 
present in strain M186 (red squares, D) and all associated ones from the mixed human-bovine group Ib 
(M319 and M308). The prophage present in strain M124 at c.a. 370K bp was also present in strains 
from group Ia but absent from subgroup Ic (result not shown). An incomplete prophage was also 
predicted at c.a. 993 Kbp in all CC8 bovine strains. (B) UV-induced excision of β-hemolysin-converting 
bacteriophages after UV exposition of strain M186, hemolysis was observed around certain colonies. 
This phenotype was due to the loss of the β-hemolysin-converting prophages that restore the hemolytic 
activity of the strain. Prophage excision was confirmed by multiplex PCR using primers for the 
amplification of the staphylokinase (sak) and the integrase present on the prophage or the β-hemolysin 
(Hlb). (C) The introduction of the lipase converting bacteriophage from strain M124 (subgroup Ia) into 
strain M186 was also achieved and phenotypic conversion regarding lipase activity was observed as 
presented in panels (E), parent strain M186 growing on tributyrin-containing plates and  (F): strain M186 
in which the lipase interrupting phage of strain M124 was introduced and grown on tributyrin-containing 
plates.  
 
Prophage curing and reintroduction in bovine CC8 isolates. To further study the 
implication of prophages in the host-jump, we attempted to cure and reintroduce 
prophages in the prototypic strain M186 (which belongs to the human-bovine subgroup 
Ib and contains only the β-hemolysin prophage) in order to obtain a series of strains 
encompassing subgroups Ia (human-bovine, with 2 prophages) to Ic (bovine only with 
no prophages).  
We first, succeeded in curing strain M186 (human-bovine subgroup Ib) form its β-
hemolysin-converting prophage by exposing it to UV radiation. Indeed, UV light is 
known to generate stress by inducing DNA damage that induces prophage excision 
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(Figure 5.B and 5.C). Because phage-excision is supposed to restore the phage-
interrupted β-hemolysin gene, it was possible to screen for colonies producing 
hemolysis on blood agar (Figure 5B and 5C). As a mirror experiment, the β-hemolysin-
converting prophages could also be reintroduced in the bovine-only strain M117 
(bovine-only subgroup Ic) by incubating it with mitomycin C induced supernatant from 
strain M186 and screening for the loss of hemolysis on blood agar (results not shown).  
The same experiments were also performed with the lipase converting bacteriophage 
(Figure 5.E and 5.F). To this end strain M124, which contained two prophages 
(subgroup Ia) was induced by UV exposure as above. Then, strain M186 was exposed 
to the phage-containing supernatant and platted of tributyrin-containing agar to screen 
for colonies that had lost a lipolytic halo. All phage losses and acquisitions were 
confirmed by PCR.  
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Discussion and perspectives 
The present study aimed at shedding a comprehensive light on the genealogy and 
mechanistic events involved in the putative human-to-bovine host jump of CC8 S. 
aureus. We first reconstructed the phylogeny of human and bovine isolates based on 
core genome genes. This refined genealogy confirmed previous assumptions of the 
human-to-bovine directional jump based on AFLP, MLST [22] and microarrays [24]. 
Indeed, while microarray analysis – which is restricted to the presence or absence of 
known genes – showed that 98% of the differences between human and bovine 
isolates were related to MGEs, the present results indicate that human and bovine CC8 
isolates differed in even more intrinsic features that resided in their core genome 
genes. This highlights the depth of the divergent evolution of originally human-
anchored CC8 strains, which at a certain point of time gave rise to a unique bovine 
branch. Moreover, while the present observations addressed the directional jump from 
the side of the human host, veterinary epidemiologic studies came to the same 
conclusion from the bovine side [26]. They independently disclosed that a recently 
described particularly invasive bovine mastitis S. aureus, referred to as genotype B (or 
GTB), was identical to human CC8 and was likely to be a descendant of this very 
human staphylococcal clonal complex.  Even more, they propose that all bovine S. 
aureus have a human ancestor. 
In the following we briefly discuss three aspects that we studies more deeply regarding 
the mechanism of this host jump, including its association with specific MGEs, the 
putative mechanisms mediated by these MGEs, and the possibility to study “reverse 
evolution” by reconstructing the dynamic of the MGE trafficking responsible for the host 
jump. 
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MGEs associated with the host jump. In addition to the global genealogy discussed 
above, the present analyses also underlined the dynamic of acquisition and loss of 
MGEs that happen along the human-to-bovine passage. Microarray analyses 
classified human and bovine CC8 in 3 subgroups (Ia, Ib and Ic) where the acquisition 
of SCCbov, found only in bovine strains, clearly discriminated between human and 
bovine isolates [24]. In this very study, the Ia and Ib subgroups contained mixt human 
and bovine isolates, all of which carried the β-hemolysin-converting prophage, while 
only bovine isolates carried the additional SCCbov. In contrast, the third subgroup (Ic) 
contained only bovine isolates, all of which had lost the β-hemolysin-converting 
prophage. This suggested a progressive passage from Ia to Ic, but without a clear clue 
explaining the difference between the mixt human-bovine subgroups Ia and Ib.  
The present results confirmed these three subgroups from the core genomic point of 
view. Moreover, they added critical information regarding the passage from subgroup 
Ia to Ib. Indeed, bovine strains of subgroup Ia carried two prophages, i.e. one lipase-
converting and one β-hemolysin-converting prophage, whereas bovine strains of 
subgroup Ib had lost the lipase-converting prophage. Finally, the bovine-only subgroup 
Ic has lost both prophages. Thus, although acquisition of SCCbov was a sine qua none 
condition for the host jump, as highlighted by core genome phylogeny, additional 
requirements such as reestablishment of lipase activity (by losing the lipase-converting 
prophage) and β-hemolysin activity (by losing the β-hemolysin-converting prophage) 
were likely to facilitate the establishment and stability of CC8 staphylococci in the 
bovine environment. 
In counterpart, the loss of the β-hemolysin-converting prophage is also likely to hamper 
the jump-back of bovine CC8 (or GTB) strains to humans. This is suggested by the 
quasi absence of bovine CC8 (or GTB) in farm-workers in previous studies [22, 26], 
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and by the fact that when they loose the β-hemolysin-converting prophage, S. aureus 
also lose the prophage-associated immune evasion cluster (ICE) carrying the 
staphylokinase (sak), enterotoxin A (sea), chemotaxis inhibitor protein (chips) and 
staphylococcal complement inhibitor (skin) genes [41].  
To further study the role of these MGEs in the host jump we first addressed the role of 
SCCbov, which was a prerequisite for the human-to-bovine passage. 
Putative role of SCCbov in the human-to-bovine host jump. SCCbov carries 
several genes that might be beneficial in the agriculture milieu, such as arsenic and 
copper resistance genes, plus one intriguing gene encoding a putative peptidoglycan-
anchored protein via the LPXTG-SortA system [24, 42]. This gene, tentatively named 
adlb (for Adhesin-Like Bovine protein) [27] is constituted of a central domain of 
unknown function, bracketed by a N-terminal and a C-terminal repeats domains, the 
latter showing homology with AAP proteins [24, 27, 40]. 
To understand the role of SCCbov and the putative ADLB protein it was critical to first 
assess its presence on the staphylococcal surface, then test the phenotype it could 
confer, and finally test whether excising SCCbov in toto or inactivating adlb would lead 
to phenotype modifications. The presence of ADLB on the bacterial staphylococcal 
was unambiguously demonstrated by LC-MS and western blot in several independent 
bovine CC8 isolates, as well after heterologous expression of adlb in L. lactis. 
Interestingly, we also observed strain-dependent variation in the length of the adlb 
gene, which translated in parallel length variation of the ADLB surface protein. These 
length variations occurred in the N-terminal and C-terminal AAP-like repeats, not in the 
central domain.  
Since length variations of LPXTG proteins may be associated with clonality, as in the 
protein A gene (spa) that gave rise to spa-typing [43], we asked whether adlb-length 
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could correlate with spa-types, which correlated with clonality in GTB (or CC8) infected 
farms [26]. Unfortunately, the number of comparable isolates was to small to draw a 
conclusion on this matter. 
Nevertheless, beyond molecular characterization is was also determinant to identify 
the putative phenotype conferred by ADLB. The first striking observation was that 
expressing ADLB in L. lactis (as confirmed by western blot) produced irregular star-
shaped colonies. In contrast, colonies losing ADLB returned to natural smooth and 
round-shaped morphologies. Thus, we expected ADLB to confer some kind of surface-
related phenotype, such as adherence to host matrix proteins or milk components, or 
to promote biofilm formation as does AAP [40]. However, these functional tests did not 
disclose differences between parent and mutant staphylococci or lactococci. 
We next attempted to identify potential ADLB host ligands by pulling down proteins 
from extracts of lactating udders using ADLB-expressing lactococci as baits. These 
experiments did not yield additional host-matrix protein that had not been tested in the 
first screening experiments, but rather oriented us to the intracellular lifestyle of S. 
aureus. Indeed, 3 out of 9 udder proteins recovered by ADLB-positive lactococci were 
related to intracellular vesicle trafficking, namely Dynein 1 heavy chain, Golgin like 
protein and Keratin type I cytoskeletal protein. This prompted us to seek a role of ADLB 
in the setting of mammary gland cell cultures.  
To this end, we generated isogenic bovine CC8 strains (using prototypic strain M186) 
from which the SCCbov cassette had been excised in toto, or in which the adlb gene 
had been inactivated. We also used the ADLB recombinant lactococci as a control. 
First, ADLB-recombinant lactococci did not show differences in mammary cell 
adhesion or internalization, indicating that ADLB was not involved in these initial steps 
of infection.  
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Second, parent and SCCbov excisants or adlb-interrupted mutants invaded cells 
similarly early after inoculation. Since ADLB alone did not mediate cell internalization 
on its own in the recombinant lactococci experiments, mammary cell uptake of S. 
aureus might have been prompted by other staphylococcal components, such as 
ubiquitous FnBPA, which mediates staphylococcal internalization in eukaryotic cells 
[44].  
Third, upon more prolonged incubation, parent staphylococci escaped endosomes and 
lysed the host cells, as assessed by optical microscopy, whereas the SCCbov and adlb 
mutants respected both the vesicles and the cells. As a result, parent S. aureus were 
released into the gentamicin-contained medium and killed by the antibiotic. In contrast, 
mutants survived for prolonged periods of time in the non-professional phagocyte 
milieu of mammary cells.  
Taken together, these experiments indicate that at least one effect of ADLB is vesicle 
escape and lysis of host cells. The exact mechanism by which this occurs is as yet 
unclear, but it is linked to the presence of ADLB, plus or minus other non-SCCbov 
proteins (FnBPs, β-hemolysin etc), since no difference was observed between 
SCCbov excisants and adlb mutants. Moreover, whether processing and release of 
ADLB by bovine CC8 staphylococci is important is a matter of speculation. Indeed, 
releasing polypeptides able to bind dynein-motor and cytoskeleton structures inside 
mammary host cells could contribute to paralyzing the natural vesicle addressing such 
as lysosome formation and thus promote intracellular staphylococcal survival. 
The invasive phenotype associated with ADLB could potentially explain privileged 
bacterial multiplication of bovine CC8 (or GTB) strains in the bovine milieu, and thus 
non-specific (bulk-related) spread within cowherds. However, it does not explain its 
propensity to preferentially colonize lactating udders and milking apparatuses [26]. A 
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hint to this explanation could emerge from the trafficking of prophages, which is 
addressed next. 
Potential role of prophage trafficking in the human-to-bovine host jump. 
Acquisition or loss of prophages and prophage-related genes play a well-known role 
in microbial adaptation and pathogenicity [45]. Salient examples regarding S. aureus 
include prophage-encoded Panton-Valentine leukocidin and exfoliative toxin A [46, 47]. 
Moreover, acquisition and loss of prophages were also associated with human-animal 
exchanges of S. aureus, as exemplified by human-poultry and human-porcine jumps 
[18, 48]. In these two examples, poultry- and porcine-adapted S. aureus lost the ICE-
carrying β-hemolysin prophage typical of human strains, and poultry strains acquired 
a new prophage instead (Phage AVβ) encoding for proteases that might be important 
in the avian niche.  
The present observation between human and bovine hosts implies the sequential loss 
of two prophages. The first, interrupting the lipase gene, has not yet been involved in 
human-animal host jumps, while the second, interrupting the β-hemolysin gene, was 
associated with the human-porcine jump [48]. To study the putative role of the loss of 
these two prophages we used prototypic strain M186 (from the mixt human-bovine 
subgroup Ib) containing only the β-hemolysin-converting prophage and generated two 
recombinants: one from which we excised the β-hemolysin-converting prophage, 
generating a bovine-only subgroup Ic prototype, and one in which we inserted the 
lipase converting prophage of subgroup Ia strain M127, generating a mixt human-
bovine subgroup Ia prototype. This M186 triad, containing SCCbov and spanning the 
three Ia, Ib and Ic prophage subgroups is now being used to determine their role in 
lipid-rich milked environment, for the lipase converting prophage, and mammary cell 
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adherence, β-hemolysin was previously reported to facilitate epithelial colonization 
[49]. 
Conclusion and perspectives. Taken together, these present results highlight the 
sophisticated interplay between complementary actors involved in the CC8 (or GTB) 
human-to-bovine host jump. Although SCCbov cassette and ADLB were central to the 
host jump (no human strains possessed them), it relied on parallel losses of lipase- 
and β-hemolysin-converting prophages, which were present in human-only strains but 
totally absent from bovine-only strains. On this basis we propose the following 
scenario: 
 
1. Restoring lipase activity (loss of lipase-interrupting prophage) could promote 
growth in lipid-rich lactating udder environment. 
2. Restoring β-hemolysin (loss of β-hemolysin-converting prophage) might promote 
epithelial colonization as previously shown in animal models.  
3. Fibronectin-binding protein, which is ubiquitous in S. aureus, promotes 
internalization into mammary cells, as previously demonstrated. 
4. ADLB promotes endosomal escape and mammary cell lysis, allowing further 
spread and explaining the virulent phenotype of this peculiar clone. 
While the role of the prophage trafficking is the purpose of current studies, these results 
suggest new approaches to enrich the preventive armamentarium against this 
particular organisms, first by proposing a new detection test to improve sanitation [27], 
and second by suggesting new vaccine targets for blocking antibodies against CC8 (or 
GTB) determinants, such as ADLB, lipase and β-hemolysin. 
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Supplementary Tables 
Table 1: Bacterial strains and their origins, plasmids and nucleotides 
Bacterial strains Characteristics Origin 
   
E. coli    
DH5α/pORI23  [34] 
DH5α/pORI23-ADLBM186  This study 
DH5α/pORI23-
ADLBM186ΔLPXTG 
 This study 
DH5α/ pPGFP-N315  [28] 
   
L. lactis   
L. lactis subsp. cremoris 
1363 
 [50] 
L. lactis pORI23-
ADLBM186 
 This study 
L. lactis pORI23-
ADLBM186ΔLPXTG 
 This study 
 
S. aureus   
RN4220 Restriction-deficient derivative of RN450; 
intermediate cloning host 
[51] 
N315 MRSA carrying type II SCCmec [52] 
M186ΩDALB DALB inactivation by transposon insertion This study 
M186ΔSCC_bov SCC_bov element excised form  strain M186 This study 
 63 
 
M186Δφβhem Beta-hemolysin converting prophage excised 
from strain M186 
This study 
M186::φlipM124  Lipase converting prophage present in strain 
M124 introduced in strain M186 
This study 
I37 Human isolate [22] 
Laus385 Human isolate [22] 
Laus102 Human isolate [22] 
MBk Isolated from milk sample H. Graber 
I2 Human isolate [22] 
MBc Isolated from milk sample H. Graber 
I292 Human isolate [22] 
Laus270 Human isolate [22] 
I369 Human isolate [22] 
F173 Human isolate H. Graber 
MG34 Isolated from milk sample H. Graber 
MJb Isolated from milk sample H. Graber 
MO103 Isolated from milk sample H. Graber 
Mje Isolated from milk sample H. Graber 
MO100 Isolated from milk sample H. Graber 
M2872 Isolated from milk sample H. Graber 
M5 Isolated from milk sample [22] 
M534 Isolated from milk sample [22] 
M308 Isolated from milk sample [22] 
MJn Isolated from milk sample H. Graber 
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MG018 Isolated from milk sample H. Graber 
MG36 Isolated from milk sample H. Graber 
M192 Isolated from milk sample [22] 
M160 Isolated from milk sample [22] 
M86M Isolated from milk sample [22] 
M283 Isolated from milk sample [22] 
MFU1 Isolated from milk sample H. Graber 
MG57 Isolated from milk sample H. Graber 
M92 Isolated from milk sample [22] 
M319 Isolated from milk sample [22] 
M37 Isolated from milk sample [22] 
M117 Isolated from milk sample [22] 
M313 Isolated from milk sample [22] 
M222 Isolated from milk sample [22] 
M20 Isolated from milk sample [22] 
MG03 Isolated from milk sample H. Graber 
M1092 Isolated from milk sample H. Graber 
M385 Isolated from milk sample [22] 
M124 Isolated from milk sample [22] 
M125 Isolated from milk sample [22] 
M2117 Isolated from milk sample [22] 
M1172 Isolated from milk sample [22] 
M186 Isolated from milk sample [22] 
MG16 Isolated from milk sample [22] 
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MG04 Isolated from milk sample H. Graber 
   
Plasmids   
   
pOri23 ermAM ori ColE1 P23 [34] 
pORI23-ADLBM186 DALB cloned into pORI23ermAM ori ColE1 P23 This study 
pORI23-ADLBM186 DALB with 6-his tag inserted into the LPXTG 
signal cloned into pORI23ermAM ori ColE1 P23 
This study 
pPGFP-N315p ccrAB promoter fusion with GFP cloned in 
pCN36; tet(M) 
[28] 
 
Oligonucleotides 
 
 
 
 
LPXTG_DALB_SalI ACGCGTCGACTTATTGGGAGGTAATAATATG
GAAAAAAG  
This study  
LPXTG_DALB_PstI AAAACTGCAGTTATTTTTCACTATTATCCTTAT
TTTTACG 
This study 
IBS AAAAAAGCTTATAATTATCCTTAACTCTCAAT
ACAGTGCGCCCAGATAGGGTG 
This study 
IBS1d 
 
CAGATTGTACAAATGTGGTGATAACAGATAA
GTCAATACAGGTAACTTACCTTTCTTTGT 
This study 
IBS2 TGAACGCAAGTTTCTAATTTCGATTAGAGTTC
GATAGAGGAAAGTGTCT 
This study 
ADLB_fw TTGGAAAAAAGAAGACAAGGCCC This study 
Fw4200_ADLB GTTCCTGTAGTACTTGTC This study 
hlb-2  AGCTTCAAACTTAAATGTCA This study 
hlb-527 CCGAGTACAGGTGTTTGGTA This study 
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13int-for GCTTTGAAATCAGCCTGTAG This study 
sak-for GTGCATCAAGTTCATTCGAC This study 
sak-rev TAAGTTGAATCCAGGGTTTT This study 
lip2_Fw  GTTAGATGGCTCTGCAAAATTG This study 
Lip_366_Rv  CTTCACCAACACCGGTTGTTC This study 
Lip_int_Rv CGAGAAGTACAAAGATCCATAC This study 
Q5SDM_ADLB_F CACCACCACAAAGACCGTCAAAATAATGAAG This study 
Q5SDM_ADLB_R ATGATGATGTGAATTCTTGTTGTTTGTTGAAT
G 
This study 
   
 
a Abbreviations: Camr, chloramphenicol resistance; Kanr, kanamycin resistance b Centre hospitalier 
universitaire vaudois (CHUV, Switzerland) c Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ, Leibniz-Institut, Germany) d American type culture collection (ATCC, Manassas, Virginia, USA) 
e Restriction sites are underlined.  
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Supplementary Figures 
 
Supplementary Figure 1. Generation of a knockout construction for the LPXTG-Bov gene present in 
strain M186 using site-specific transposon insertion. (A) A shift in the LPXTG-Bov M186 gene due to 
transposon insertion was observed after PCR amplification on the M186 WT and the M186 Δ LPXTG-
Bov M186 strains. (B) Absence of the protein on the surface was confirmed by gel electrophoresis 
(Coomassie blue staining) and (C) and western blotting. Arrows indicate the presence of the protein in 
the WT. 
 
 
Supplementary Figure 2. Detection of ADLBM186 on L. lactis / pORI23-ADLBM186 surfaces by LC-
MS/MS. Amino acid sequences of the protein that matched with the peptides analyzed by LC-MS/MS 
are highlighted in yellow or green (methylated animo acids). 
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Supplementary Figure 3. (A) The same set of primers that were used to amplify the adlbM186 were used 
on other CC8 bovine strains. PCR products ranged from c.a. 3.5 Kb (M186) to 6.5 Kb (M2117) showing 
interspecies variation. (B) Different sets of primers were designed to amplify the regions containing 
repeats. Size variation observed in Figure A is due to size variation in the repeated region 
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Supplementary Figure 4. A western blot with protein extracts present in the supernatant of CC8 strain 
M186, 5, 20, 124, 1172, 117, 160, 222, 308 and G34 that are ADLB positive and CC8 strain MBk that is 
ADLB negative was also prepared. All Protein extracts and Western blots were prepared as already 
described [34]. Image (A) was taken with a camera and image (B) with film after the first one get out of 
order.   
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Supplementary Figure 5. (A) Structural similarities between the ADLB and Agglutination Associated 
Proteins (APP). AAP contains an N-terminal A-repeat region with degenerate 16-aa repeats, a globular 
domain (α/β), and a B-repeat region with a variable number (5 to 17) of nearly identical 128-aa G5 
domains. (Adapted from reference [53]). (B) Proposed mechanism of action for AAP. The B-repeats will 
spontaneously cleave, which will trigger G5 domain polymerization and ultimately bacterial aggregation 
[38].  
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Supplementary Figure 6. Bovine CC8 strains shared a similar cumulative GC skew as the one 
presented in A. An inversion in the cumulative GC skew between c.a. 993 and 995 Kbp was always 
observed and correspond to the integration site of the incomplete prophage (B). 
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Chapter II 
 
 
Intramolecular regulation of bacteriophage lysins explains complex 
multi-domain architecture and prevents untoward lysis of 
neighbouring bacterial cells  
 
 
 
Siphoviridae. Negative staining. 2016. F. Oechslin 
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General introduction.  
Bacteriophages (phages) are bacterial viruses that can be found in extremely different 
environments [54] and are known to be the most diverse and abundant biological 
entities on earth [55]. They are currently classified in more than ten different families 
according to their morphology and nucleic acid composition [56]. Nevertheless, 95% 
of them belong to the order of Caudovirales, which is composed of tailed morphotypes 
with a double stranded linear DNA [56]. Since phages are obligate parasites that do 
not have an independent metabolism, they need to infect a bacterial host in order to 
replicate. It is during this infection process that phages, depending on their type, can 
follow a lysogenic or a lytic life cycle. In the lytic cycle, replication of phages is followed 
by the destruction of the host bacteria.  
 
 
Figure 1. In the lytic cycle, phage replication pass through five main steps that are 1) the attachment of 
the phage to his host, 2) the injection of the viral DNA, 3) the hijacking of the cell molecular machinery 
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in order to replicate the DNA and synthesize structural components, 4) the assembly of the newly 
produced phages and 5) the release from the host by its lysis. In the lysogenic cycle, phage DNA is 
circularized after injection (6) and integrated into the host genome (7). Adapted from [57]. 
 
In the lysogenic cycle, the phage genome is first integrated into the host chromosome 
as a prophage and can stay integrated and replicates with the host chromosome until 
an induction event occurs. Events that induce prophage excision imply host cell 
damage, such UV light or chemicals, which are generally related to the bacterial SOS 
response.  
Excised prophage genomes can then re-enter the lytic cycle, including DNA replication, 
protein synthesis and capsid assembly and eventually host cell lysis and release of the 
phage progeny. Bacterial lysis at the end of the replication cycle is due to the 
coordinated action of two phage proteins forming the holin/lysin system. In this two 
component system, holin is produced in order to form holes in the inner membrane so 
that the lysin, which is a peptidoglycan hydrolase enzyme, can attack the cell wall of 
the bacterial host and induce cell lysis [58]. 
It is only relatively recently that phage lysins were considered as potent antimicrobial 
agents and used to control gram-positive bacterial infection in different animal models 
[59, 60]. Since gram-positive bacteria are lacking an outer membrane (in contrast to 
their gram-negative counterparts), it is indeed possible to add lysins from the outside 
of the cell to disrupt the bacterial cell wall and kill the bacteria.   
Gram-positive phage lysins usually have a modular structure, which includes one or 
more catalytic domains (CD) and cell wall binding domains (CBD) linked together by a 
short linker [61, 62]. Depending on which bonds of the bacterial peptidoglycan are 
hydrolysed, lysins can be categorized in four main groups including glucosaminidases, 
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muramidases, amidases and endopeptidases, respectively (see Figure 2). 
Interestingly, it was observed that different lysins sharing the same catalytic activities 
had higher homologies between their CDs than their CWBDs [63]. The CWBD domain 
can mediate high bacterial specificity and help the enzyme to get properly positioned 
in order to degrade its peptidoglycan substrate [64, 65]. This is specially the case for 
the Cpl-1 muramidase, which CWBD helps the orientation of the enzyme and confers 
a high specificity for Streptococcus pneumoniae via attachment of the CWBD to 
choline-containing teichoic acids in the peptidoglycan [62, 66]. 
 
 
 
Figure 2. Lysins can be classified depending on the peptidoglycan subunits they hydrolyse. The 
muramidase (N-acetlymuramidases or lysozyme) and glucosaminidase (endo-β-N-
acetylglucosaminidases) hydrolyze the glycosidic bonds of the glycan strand. The amidases (N-
acetylmuramoyl-L-alanine amidases) are known to cleave the amide bond that link the MurNAc sugar 
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with the peptide strand and endopeptidases cleave inside the the peptide crosslink [67]. Adapted from 
[68]. 
 
 
Currently, a large number of phage lysins have been described for all major pathogens 
including S. pneumoniae, from which the Cpl-1 enzyme was isolated. Cpl-1 is one of 
the best-studied lysin since it was tested in different murine models and in combination 
with antibiotics and other lysins [69-74]. Other enzymes specific for streptococci 
include PlyC, B30, PlyGBS, LambdaSa1 and LambdaSa2, Ply30, PlySs2, LysSMP and 
PlySK1249 [68, 75-80]. The last one (PlySK1249), which is the purpose of the present 
chapter II, was isolated five years ago from a prophage carried by the bacterium 
Streptococcus dysgalactiae subsp. equisimilis SK1249. The lysin harboured a singular 
structure composed of a central binding domain (CWBD) surrounded by a N-terminal 
amidase domain and a C-terminal cysteine histidine-dependent 
amidohydrolase/peptidase (CHAP) domain [80]. The purified form of the enzyme was 
highly lytic both in vitro and also in vivo in a mouse sepsis model [80].  
It is actually not uncommon for streptococci phages to have a modular architecture 
with more than one catalytic or binding domains. For example, this is the case for the 
B30 lysin that has two catalytic subunits, a CHAP domain with an endopeptidase 
activity and an acetylmuramidase domain (Acm) with a glycosidase activity [68]. 
Interestingly, inactivating mutations introduced in the CHAP domain demonstrated that 
CHAP was responsible for nearly all the lytic activity of the enzyme [81]. Similar 
observations were made with the PlyGBS lysin, which shares 99% identity with lysin 
B30 [82]. The LambdaSa2 and PlsS2 were also observed to have a similar structure 
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with two Cpl-7 binding domain in the central position and two flanking catalytic domains 
with one observed to be silent [77, 83].  
Another example of even more complex architecture is the example of PlyC, which 
crystallographic analysis revealed an atypical multimeric structure. Indeed, the enzyme 
is composed of a single PlyCA catalytic subunits containing a CHAP domain with an 
amidase activity assembled with eight PlyCB molecules structured in an octameric ring 
having a CBD function [75] [65]. The two subunits were also observed to be transcribed 
from two distinct genes found in an operon like structure.  
However, the purpose of multi-modularity is actually still not very clear since two or 
more domain organizations are dominant among gram-positive lysins, but usually not 
observed among gram-negative lysins, which lack the binding domain [84].  
For instance, the benefit of a second catalytic domain is still open to debate since it is 
usually observed to be silent. Hence, it was hypothesized that it could act as a second 
binding domain or be on the way to get lost through evolution [85, 86]. Moreover, no 
clear consensus could emerge regarding the functional implication of the binding 
domain in either host specificity or as lysis helper, since different lysins were variously 
dependent on their CWBD for optimal activity [76, 81, 83, 87-91]. In addition, it was 
hypothesized by others that the CWBD could actually help to block diffusion of the lysin 
in order to prevent accidental lysis of neighbouring bacteria [92, 93]. Lysing 
neighbouring cells could result in abortion in sister bacteria carrying sibling prophages 
or destruction of phage-naive bacteria representing potential new preys. 
Although never experimentally demonstrated, this hypothesis makes sense since 
biofilms are considered as the main form of bacterial life style in most of natural 
environments [94]. It is into this very dense environment that prophage genes were 
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also observed to be the most upregulated [95, 96]. As discussed in the first chapter of 
the present thesis, prophages contribute to bacterial genome diversification by 
introducing novel genes and also regulate host genes by acting as genetic switches as 
they can disrupt or restore gene expression during integration or excision. The 
prophage content of bacteria should probably not be seen as static situation, but rather 
as a more dynamic process with phages permanently escaping and reintegrating a 
subpopulation present in the biofilm. For this reasons, it is not impossible that post-lytic 
regulation mechanisms are existing in order to control and restrict diffusion of these 
highly lethal lytic enzymes. 
It is already known that phage-induced bacterial lysis is a highly regulated event since 
it takes place only at the very late stage of phage infection. For this reason, a large and 
extended diversity of mechanisms impacting on endolysin activity can be observed for 
various phages at the transcriptional and posttranscriptional level. For example, in the 
case of the T4 phage it was shown that the transcription of the lytic genes started very 
early on, but that protein synthesis was delayed to the end of the replication cycle due 
to a hairpin structure adopted by the mRNA [97, 98]. Likewise, different regulation 
mechanisms exist at the posttranslational level, including regulation during 
translocation and inactivation of the lysin. Indeed, since the lysin has to pass through 
the plasma membrane, the timing can be controlled by oligomerization of the holin, 
which then permits passive diffusion of the lysin to the cell wall. Moreover, holin-
independent regulation systems were also observed for in some phages, in which the 
lysin is translocated with the help of a N-terminal secretion signal sequence SAR 
(Signal-Arrested-Release) [99]. In addition, it was observed that the lysin has to lose 
its SAR sequence by proteolytic cleavage in the periplasmic space in order to become 
activated. Regulation by inactivation was also observed as some phages do export 
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they lysin in a holing-independent manner but still produce holins. In this case, the lysin 
remains inactive in the periplasmic space until depolarisation of the membrane occurs 
by the activity of the holin [100]. 
In the manuscript presented next (to be submitted for publication), we tried to clarify 
both the roles of the CDs and the CWBD in the recently described S. dysgalactiae 
phage lysin PlySK1249, as well as the mechanism(s) that regulate the enzyme activity 
at the level of the peptidoglycan cell wall.  
In the first part, we tested different truncated versions of the PlySK1249 lysin – 
containing different active domains dissociated or linked together – against a panel of 
different gram-positive cocci. We could make three main observations regarding cell 
lysis:  
- First the native enzyme was always more active that it’s truncated versions.  
- Second the amidase domain was more active in presence of the binding 
domain. 
- Third the CHAP domain was not bacteriolytic senso stricto in bacterial cultures. 
Although this third observation was similar to the silent domains described in the 
literature by others regarding multidomain lysins, a more detailed analysis of the macro 
and chemical structure of the cell wall revealed that CHAP was in fact active. Indeed, 
light and electron microscopy highlighted morphological changes of bacteria treated 
with CHAP alone, including a dechaining activity of the enzyme as well cell surface 
alterations with an irregular appearance. Moreover, we could observe that both 
amidase and CHAP domains synergized at lysing bacteria when mixed together in an 
equimolar concentration.  
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Importantly, all these observations could be confirmed at the molecular level using 
HPLC and LC-MS peptide sequencing. Although the amidase domain disconnects the 
glycan chains from the stem peptides, as expected, it could not resolve cross-linked 
stem peptides multimers to simpler structures. In sharp contrast, CHAP resolved cross-
linked stem peptides but was unable to disconnect glycans from peptides. In addition, 
peptide sequencing of the degradation products revealed that the CHAP domain was 
able to hydrolyse the stem peptide multimers (from trimers to heptamers) down to 
dimers, but virtually never to monomers. These observations clearly explain why both 
domains can synergize and also why the CHAP domain does not directly lyse cells, 
since the glycan strands can still remain connected though dimer crosslinks. 
In the second part we focused on the CWBD. In the context of this enzyme, the role of 
the CWBD was actually not to confer specificity regarding the bacterial host range, but 
rather to first position the enzyme for appropriate lysis, and then retain the lysin to the 
wall and wall debris in order to prevent its diffusion in the surrounding milieu. In other 
words, a dual lysis-promoting and lysis-preventing function with regard to its bacterial 
host and its bacterial neighbours, respectively. 
Regarding the lysis-preventing function, we most interestingly observed that the lysin 
was subject to proteolytic cleavage by host proteases during the cell lysis process, 
which lead to two degradation products composed of an amidase-CWBD moiety and 
a CHAP moiety. Hydrolysis was observed to take place on both inter-domain linkers 
but was prevalent on the LysM-CHAP link in the presence of the peptidoglycan 
substrate. This led to an amidase-CWBD domain, which could digest the proper host 
wall, but could not diffuse because it remained attached to the wall debris (via the 
CWBD) and a CHAP domain, which was not bacteriolytic on its own even in the case 
of diffusion. 
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Taken together, we observed that both catalytic domains of the enzyme were active 
and acted coordinately with the CWBD to both ensure bacterial lysis of the host, thus 
helping the release of the phage progeny, and prevent further diffusion after host 
proteolytic cleavage, in order to restrict lysis to the lysing host bacterium and prevent 
collateral lytic damage of other cells.  
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Abstract 
Lysins are peptidoglycan hydrolases produced at the end of the phage life cycle to lyse 
the host cell. However, this may also release lysins in the environment and 
detrimentally kill neighbouring cells carrying sibling prophages or potential new 
bacterial preys. This is particularly true for Gram-positive bacteria, which lack an outer-
membrane protection. Here we show that the multi-domain architecture of Gram-
positive Streptococcus agalactiae prophage lysin PlySK1249 prevents this 
phenomenon. PlySK1249 reunifies three functional domains, including two 
peptidoglycan-hydrolases – i.e. one amidase (Ami) and one endopeptidase (CHAP) – 
and one cell-wall binding domain (CWBD). Molecular dissection revealed that all three 
domains synergized for full bacterial lysis, in spite of the fact that CHAP was marginally 
active and CWBD only mediated binding of PlySK1249 to the wall. Moreover, while the 
CWBD helped position the lysin for optimal peptidoglycan digestion, also prevented its 
further diffusion by keeping it attached to wall debris after bacterial lysis. Finally, cell 
wall associated proteases promoted catalytic cleavage of PlySK1249 between 
Ami_CWBD and CHAP, thus inactivating the lytic Ami/CHAP synergism while retaining 
the Ami_CWBD moiety to wall debris. Thus, altogether the three domains acted 
coordinately to optimize bacterial lysis while curbing lysin diffusion and inactivating it 
after lysis completion. In addition, bacterial wall protease(s) contributed to restricting 
exuberant cell destruction by inactivating the lysin in situ.  
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Introduction 
Phage lysins represent a fascinating family of peptidoglycan hydrolases that are 
indispensable for bacterial lysis and release of the phage progeny at the end of its 
replicating cycle [101]. They have gained recent interest in biomedical development as 
potential antibacterial agents [92, 102, 103]. The target of phage lysins is the bacterial 
peptidoglycan, an essential bacterial structure made of a complex meshwork of N-
acetylglucosamine (GlcNAc) – N-acetylmuramic acid (MurNAc) glycan strands cross-
linked by short stem peptides attached to MurNac residue (reviewed in [104, 105]). 
Phage lysins cut either between the sugars or peptide chains.  
Lysins come in a variety of multi-modular forms that may have evolved in order to adapt 
to their bacterial hosts. They are usually composed of several functional domains 
including glucosaminidases, amidases and endopeptidases (referred to as catalytic 
domains or CDs) and cell wall-binding domains (referred to as CWBD), which are 
believed to help position the catalytic domains in the peptidoglycan [61]. However, 
several questions remain open regarding their function in the phage biology. For 
instance, what is the purpose of multi-modularity? What determines their bacterial 
specificity? How are they regulated in order to prevent accidental lysis of neighbouring 
bacteria, which could result in abortion in sister bacteria carrying sibling prophages or 
destruction of phage-naive bacteria representing potential new preys? This may be 
particularly relevant in Gram-positive bacteria, which lack an outer-membrane barrier 
and are thus more prone than their Gram-negative counterparts to lysin-induced lysis 
from outside. In this regard, there are indeed some structural differences between 
Gram-positive and Gram-negative phage lysins, which most of the time lack a CWBD 
domain [106].  
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In lysins from gram-positive bacteria the architecture and functions of CDs and CWBDs 
are quite variable. For instance, the well characterized staphylococcal lysins Lysk, Ф11 
and MV-L, as well as the streptococcal lysins B30 and lSa2 contain two CDs and one 
CWBD [68, 77, 107-109]. However, when individually tested in truncated constructs 
only one of these CDs conferred bacterial lysis. This was exemplified by the Isa2 lysin, 
which possesses both an endopeptidase and a glucosaminidase domain, but where 
only the endopeptidase conferred bacterial lysis [86]. Similar observations were made 
with the unrelated streptococcal lysins B30 and PlyGBS, which are 99% identical, 
where bacterial lysis was solely due the amidase and not the glucosaminidase domain 
[81, 82]. Likewise, staphylococcal phage lysins LysK and Ф11 carry a lytic 
endopeptidase and a non-lytic amidase [87, 91, 110]. The reasons for conserving 
these non-lytic domains is currently unclear and hypotheses have been made 
regarding a possible loss through evolution or an implication in reinforcing cell wall 
binding. 
CWBDs are thought important for addressing and positioning the CDs in the 
peptidoglycan [111-113], and conferring the lysin specificity to their target bacteria. 
CWBDs are commonly located at the N- or C-terminals of the lysins and rarely in the 
central region [64, 114]. However, CWBDs are not always necessary for bacterial lysis 
and deleting them even improved the lytic activity of some lysins, without a loss of 
specificity in the case of lysin B30 [76, 81, 83, 87-91]. Hence, CWBDs may have 
additional roles in the lysin physiology.  
In this work we attempt to clarify the roles of the CDs and the CWBD in the recently 
described Streptococcus dysgalactiae phage lysin PlySK1249. This lysin is unusual in 
that its CWBD (called LysM for Lysin Motif) occupies a central position (see Figure 1A) 
and is bracketed by a predicted amidase domain at its N-terminal side and a predicted 
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“cysteine histidine-dependent amidohydrolase/peptidase” (CHAP) domain at its C-
terminal side. Amidases (or N-acetylmuramoyl-L-alanine amidases) hydrolyze the 
amide bond between the N-acetylmuramoyl glycan moiety and the first L-Ala from the 
stem peptides, thus separating the glycan strands from the stem peptide network [115]. 
On the other hand, CHAP domains are primarily endopeptidases, sometimes with 
amidase activities [116]. Amidase and CHAP domains are often combined in 
bifunctional lysins [87, 117, 118]. 
We tested a variety of truncated PlySK1249 constructs and made several original 
observations regarding its structure-function relation and lysis regulation. First, in 
contrast to other reports [81, 82, 86, 87, 91, 110], we observed that the amidase and 
CHAP domains synergized for both lysing whole bacteria and digesting purified 
peptidoglycan to completion. This was the case even if the CHAP domain was 
observed to be “silent” regarding its lytic activity when overexpressed alone.  
Second, the CWBD did not confer specificity of the lysin to peculiar bacterial species, 
as often believed, but rather retained the lysin to the wall and wall debris, 
simultaneously promoting lysis and preventing lysin diffusion and untoward lysis of 
neighbouring bacteria.  
Third, while PlySK1249 was stable in buffer solution, it underwent proteolytic cleavage 
in the presence of bacteria and protein cell wall extract. Hydrolysis was observed to 
take place on both inter-domain linker but was prevalent on the LysM_CHAP link in 
presence of the substrate. This led to a degradation product composed of a lytic 
amidase_LysM part, which could possibly not diffuse because it remained attached to 
the wall debris (via the CWBD) and a CHAP domain, which was note bacteriolytic on 
its own even in the case of diffusion. 
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Thus, taken together, the two CDs and the CWBD of PlySK1249 act coordinately to 
first ensure bacterial lysis and then curb its activity and diffusion in order to restrict lysis 
to the lysing bacteria and prevent collateral lytic damage. 
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Methods 
Cell culture and growth conditions. All bacterial strains used in this study are listed 
in Table 1. Gram-positive bacteria were grown at 37°C in Brain Heart Infusion (BHI, 
Becton Dickinson, New Jersey, USA) and plated on Mueller Hinton agar with 5% sheep 
blood (bioMérieux SA, Marcy l’Etoile, France). Broth cultures of streptococci and 
enterococci were grown without agitation. Escherichia coli were cultured at 37°C in 
Lysogeny Broth (LB) with agitation (220 rpm) or plated on Lysogeny Broth Agar (LA). 
The following compounds (at final concentrations) were added to the media when 
necessary: kanamycin sulfate (30 μg/ml), chloramphenicol (25 μg/ml for LA plates and 
50 μg/ml for LB) or isopropyl β-D-1-thiogalactopyranoside (IPTG) (0.4 mM). Culture 
stocks were prepared from cells in the exponential growth phase in 20% glycerol 
(vol/vol) and stored at -80°C. All chemicals were reagent grade commercially available 
products. 
 
Cloning and purifying of the different truncated version of the PlySK1249 
enzyme. To clone truncated forms of the PlySk1249 lysin (Figure 1.A), the plasmid 
pPlySK124928a [80] was used as a template for PCR amplification using the specific 
primer pairs listed in Table 1 (Microsynth AG, Balgach, Switzerland). PCR products 
were digested using restriction enzymes NcoI and XhoI (Promega, Madison, WI, USA), 
and ligated into the expression vector pET28a. The different plasmids obtained, 
namely, pAmi28a, pAmi_LysM28a, pLysM_CHAP28a, pLysM28a (Supplementary Table 1), 
were transformed in One Shot BL21 (DE3)pLysS chemically competent E. coli cells 
(Life Technologies Europe B.V., Zug, Switzerland). Constructs were purified by affinity 
chromatography as described before [80] and loaded in NuPAGE 4-12% BisTris gels 
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(Invitrogen, Carlsbad, CA, USA), in order to assess their purity and correct molecular 
weight. All constructs were validated by DNA sequencing using universal T7 primers.  
 
Assessment of lysin-induced bacterial lysis. Lysin-induced bacterial lysis was 
determined for the parent PlySK1249 lysin and its various truncated constructs by 
following the decrease in turbidity of a bacterial suspension as described in [80]. In 
order to assess a potential synergism between Ami_LysM and LysM_CHAP or Ami 
and LysM_CHAP, the two truncated enzymes were mixed together in different molar 
ratios ranging from 1:1 to 1:100. In vitro time-kill essays were performed as described 
in [80]. 
 
Light and Electron microscopy. S. dysgalactiae cells were incubated with the 
different lysin constructs at a concentration of 3.5 µM during 7 min for the PlySK1249 
and Ami_LysM constructs and after 1 h for the control and the CHAP domain. For light 
microscopy, cells were immobilized on 1% agarose pads and phase contrast 
microscopy images were taken with a Plan-Apochromat 100X/1.45 oil Ph3 objective 
on an AxioImager M1 microscope (Zeiss). For EM microscopy, glutarldehyde was then 
added (25% final concentration), incubation for 1 h at RT and washed with PBS. The 
same procedure was applied for metaperiodate (1% final concentration, 15 min 
incubation) and osmium tetroxide plus hexacyanoferate (1% and 1.5%, respectively. 1 
h incubation). Cells were then centrifuged and the pellets were spun down in 
microcentrifuge tubes containing melted agar. After solidification of the agar, pellets 
were embedded in epon for ultra-thin sections preparation as described [119]. 
Micrographs were taken with a transmission electron microscope FEI CM100 (FEI, 
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Eindhoven, the Netherlands) at an acceleration voltage of 80 kV with a TVIPS 
TemCam-F416 digital camera (TVIPS GmbH, Gauting, Germany).   
 
Purification and digestion of peptidoglycan. Peptidoglycan of S. dysgalactiae 
SK1249 was purified as previously described [120]. Briefly, 10 ml of an ON culture was 
added to 1 l of fresh BHI medium. The cells were grown until an OD600nm of 0.4-0.5 and 
then quickly chilled down in an ice bath for 5-10 min. The culture was centrifuged at 
4°C and resuspended in PBS to reach a total volume of 40 ml. The bacterial 
suspension was poured dropwise into 40 ml of boiling SDS (8%) and boiled with 
agitation for 15 min to inactivate intrinsic autolytic enzymes. The cells were centrifuged 
at 20°C to avoid SDS precipitation, washed twice with NaCl 1M, and 5 times with dH2O. 
After the final washing step, the bacteria were resuspended in 2 ml dH2O and stored 
at -20°C ON. The next day, the cells were broken in the FastPrep (Thermo Savant 
FastPrep FP120 Homogenizer) 3 times for 45 sec and 6.5 m/sec with a cooling step of 
5 min in between each agitation. The supernatant was transferred into a Falcon® tube 
and centrifuged for 5 min at 4°C and then again for 20 min at 4°C. The pellet was 
resuspended in 3 ml Tris (0.1 M), pH = 7.5 and 0.3 ml NaN3 (0.5%). After the addition 
of 0.3 ml MgSO4 (200 mM), 60 µl DNAse (500 µg/ml) and 60 µl RNAse (2500 µg/ml), 
the mixture was incubated for 2 h at 37°C with agitation and then ON after having 
added 0.3 ml CaCl2 (100 mM) and 0.3 ml trypsin (100 µg/ml). For the last steps, SDS 
(1% final concentration) was added to the preparation, which was then heated for 15 
min at 75°C to extract peptides from protease digestion. After centrifugation for 20 min 
at 20°C, the pellet was washed once with dH2O, resuspended in 20 ml LiCl (8M) and 
incubated at 37°C with agitation for 15 min. The mixture was again centrifuged at 4°C 
for 20 min, resuspended in 20 ml EDTA (0.1 M) and incubated another time to remove 
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material bound by ionic interactions. At last, the bacterial peptidoglycan was re-
centrifuged, washed twice and resuspended in 2 ml dH2O. Aliquots of 1 ml were 
transferred into pre-weighed Eppendorf tubes and dried ON by rotary evaporation 
(UniEquip UNIVAPO 150 ECH). The dried bacterial peptidoglycan was then 
resuspended to reach a concentration of 10 mg/ml. For enzymatic digestion, 100 µl of 
the purified cell wall was mixed with 900 µl of the previously purified lysin constructs (3 
µM). The mixture was incubated ON at 37°C with agitation. The next day, the solution 
was heated for 3 min at 100°C to inactivate the enzyme, centrifuged at 13’500 rpm for 
10 min and the supernatant containing the solubilized walls was transferred into a new 
tube.  
 
Biochemical analysis of peptidoglycan hydrolysis sites. Cell wall digestion were 
performed as described before. A modified Park-Johnson essay was used for reducing 
sugar analysis, and quantification of free amimo acids was done with a modified 
Ghuysen procedure with 1-fluoro-2.4-dinitrobenzene as described [121]. Undigested 
cell wall was used as a blank and calibration curves of glucose or L-Alanine were used 
for calculations. All experiments were performed in triplicate.  
 
Analysis of the digested peptidoglycan using reverse phase (RP) HPLC. The 
digested peptidoglycan was put at -80°C for 5 min and then dried ON by rotary 
evaporation. After the addition of 0.5 ml acetone, the tube was sonicated to re-suspend 
the pellet and 1 ml of acetone was added to remove any contaminating endotoxin. The 
tube was left at room temperature (RT) for 30 min and was then centrifuged for 10 min. 
The supernatant was decanted and again dried by rotary evaporation for 10 min. Two-
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hundred µl of dH2O was added, the preparation was sonicated and put 5 min at -80°C 
and was then dried by rotary evaporation for 2 hours. The quantity of a solution (25% 
2-propanol, 25% acetonitrile, 50% dH2O and 10% TFA) necessary to obtain a final 
concentration of about 2 mg/ml was added to the sample in order to separate the 
glycan chains from the peptides by differential precipitation. The tube was vortexed, 
sonicated and put on ice for 15 min. After centrifugation at 13’500 rpm for 15 min at 
4°C, the supernatant, containing the stem peptides and peptide bridges, was 
transferred into a new tube and frozen at -80°C until further analysis. The frozen 
peptides were dried by rotary evaporation ON and resuspended in 500 µl dH2O. To 
separate the peptides, a HPLC system (Hitachi Instruments, Ichige, Hitachinaka, 
Japan) consisting of a L-7200 autosampler, a L-7100 gradient pump, and a L-7400 UV 
detector, was used as described previously [120]. Aliquots of 100 µl were injected into 
a C18 reverse phase column (SuperPac Sephasil C18, 5 µm, 4 x 250-mm column, 
Amersham Pharmacia Biotech), which temperature was maintained at 25°C using a 
pelcooler (Lab-Source, Reinach, Switzerland). A linear gradient of 0-15% acetonitrile 
in 0.1% of trifluoroacetic acid at a flow rate of 0.5 ml/min over 100 min allowed the 
separation of the peptides, which were detected at 210 nm. The results were analysed 
with the D-7000 HPLC System Manager program (Hitachi). 
 
Mass spectrometry analyses of digested peptidoglycan. Cell wall digestion was 
performed as described before. At the end of digestion, samples were boiled at 100°C 
to stop enzymatic reaction, filtered through a 5000 MW cut-off column (REF) and 
desalted using C18 cartridge (REF). Peptidoglycan fragments were eluted with an 80% 
MeCN + 0.1% TFA solution and dried with a SpeedVac, before being redissolved in a 
loading buffer (2% MeCN + 0.1% TFA). Samples were injected on a Dionex RSLC 
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3000 nanoHPLC system (Dionex, Sunnyvale, CA, USA) interfaced via a nanospray 
source to a high-resolution mass spectrometer QExactive Plus (Thermo Fisher, 
Bremen, Germany). Peptidoglycan fragments were loaded onto a trapping 
microcolumn Acclaim PepMap100 C18 (20 mm x 100 μm ID, 5 μm, Dionex) before 
separation on a C18 reversed-phase analytical nanocolumn at a flowrate of 
0.25 μl/min.Q-Exactive Plus instrument was interfaced with an Easy Spray C18 
PepMap nanocolumn (50cm x 75µm ID, 2µm, 100Å, Dionex) using a 37 min gradient 
from 4 to 76 % acetonitrile in 0.1 % formic acid for separation (total time: 65min). Full 
MS survey scans were performed at 70,000 resolution. In data-dependent acquisition 
controlled by Xcalibur software 3.1 (Thermo Fisher), the 10 most intense multiply 
charged precursor ions detected in the full MS survey scan (250-2000 m/z window) 
were selected for higher energy collision-induced dissociation (HCD, normalized 
collision energy NCE=27 %) and analysis in the orbitrap at 35’000 resolution. The 
window for precursor isolation was of 1.5 m/z units around the precursor and selected 
fragments were excluded for 10s from further analysis. MS raw files were processed 
with PEAKS software (version 8.0, Bioinformatics Solutions Inc., Waterloo, Canada) 
for peptide identification by de novo sequencing and database search. The set of 
Streptococcus dysgalactiae subsp. equisimilis SK1249 proteome sequences 
downloaded from UniProt database (February 2016 version, 2’309 sequences) was 
used for database search of sample contamination by proteins from S. dysgalactiae, 
while peptidoglycan peptides were identified by de novo sequencing. Database search 
and de novo sequencing parameters were: no enzyme used as the enzyme definition, 
N-terminal acetylation of protein and oxidation of methionine as variable modifications, 
parent ion tolerance of 10 ppm and a fragment ion mass tolerance of 0.02 Da. 
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Enzyme-linked Immunosorbent Assay (ELISA). The adherence of lysin constructs 
to bacterial cells was assessed by ELISA. Cultures of S. dysgalactiae SK1249 were 
grown to an OD600nm of 0.5-0.6, washed once by centrifugation in PBS and 
resuspended in the same buffer. The suspensions were diluted tenfold in order to 
obtain approximately 108 bacterial cells per ml. Two-hundred microliters of the bacterial 
suspensions were adsorbed to the wells of a 96-well plates (Nunc™) and the plates 
were stored ON at 4°C. Controls were performed by adsorbing the lysin constructs in 
binding buffer at different concentrations. The wells were washed 3 times with PBS 
and blocked with 200 µl of BSA-PBS (3%) for 2 h at RT. Plates were further washed 3 
times with PBS before 200 µl of various concentrations of the lysin constructs (diluted 
in PBS) were added to the wells. Plates were then incubated on ice for 2 h. Unbound 
lysins were removed by washing with PBS and plates were incubated with primary 6X-
His Tag antibodies diluted 1:1000 in BSA-PBS 3% (100 µl per well) for 1 h on ice. The 
wells were washed with PBS and plates were incubated with polyclonal goat anti-rabbit 
immunoglobulin/HRP diluted 1:2000 in BSA-PBS (3%) (100 µl per well) for 1 h on ice. 
The plates were then washed 6 times with PBS before 100 µl of substrate (TMB 
substrate kit, Thermo Scientific, Pierce Biotechnology, IL, USA) were added to each 
well. The reaction was stopped after 15 min by the addition of 100 µl of H2SO4 and the 
signal was detected with a microplate reader at 450 nm (Tecan, Microplate Reader, 
Infinite 200 PRO, Männedorf, Switzerland). 
 
Lysin diffusion assay. This assay was designed to assess the implication of the 
CWBD in the diffusion of the lysins through bacteria embedded in soft agar. First, ON 
cultures of S. dysgalactiae were washed by centrifugation (in saline) and resuspended 
in 0.25 vol of PBS. Granulated agar (7.5 g/L) was added to the cell suspensions and 
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autoclaved 15 min at 120°C. 1 ml of solution was finally poured in 6 well plates that 
were stored at 4°C. For the assay, 4 mm diameter wells were punched in the center of 
the agar surfaces and 10 ul of enzyme at different concentrations were added into the 
pits. Diffusion was assessed by measure the diameter of the lysis halo formed after 
ON incubation at 37°C. 
 
PlySk1249 proteolysis characterization. Cell wall protein extract was prepare as 
described elsewhere [34]. The native enzyme and its different truncated version (40 
µM) were then digested ON by mixing them with half of the extract. The native enzyme 
and its different truncated version (40 µM) were also digested ON or for different time 
point by adding trypsin at 1 µM/ml. If required, purified cell wall was added to the 
reaction at a final concentration of 100 µg/ml. Reaction were stopped by incubating the 
mix with loading buffer and beta-mercaptoethanol during 15 min at 80°C. The reaction 
products were loaded on a NuPAGE 4-12% BisTris gel. Bands of interest were cut 
from the gel and amino acid sequence was identified by nanoLC-MS/MS at the at the 
protein analysis facility of the University of Lausanne (PAF, Center for Integrative 
genomic, University of Lausanne, Switzerland). Western blotting was performed as 
described before [35] and blots were incubated 1 h with a 1:1000 dilution of 6X-His 
Tag rabbit antibody (Thermo Fisher Scientific, Massachusetts, USA) following by a 1 
h incubation with a 1:3000 dilution of peroxidase-conjugated goat anti-rabbit secondary 
antibody (Thermo Fisher Scientific). Bands were detected using ECL Western blotting 
detection reagent (Amersham Bioscience. Piscataway, NJ).  
For fractionation of the cell wall protein extract, ammonium sulphate was used at 
different concentration ranging from 15% to 100%. For each fractionation steps, 
ammonium sulphate that was finely grinded was directly added to 10ml of cell wall 
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extract and let steered for 15 min at 4°C. The protein fractions were then collected 
using 4000 rpm centrifugation for 30 min. Pellets were re-suspended in 100 µl of PBS 
and mixed with 100 µl of the LysM_CHAP construct for ON incubation. Proteolytic 
activity of the different fraction was assessed by western blotting as described before. 
A second fractionation step was done by loading a 55% to 80% ammonium sulfate 
fraction on a size exclusion column (Superdex® 200 Increase 10/300 GL, GE 
Healthcare,  Little Chalfont, United Kingdom) equilibrated with PBS. The protein 
content was then eluted in 0.5-ml fractions with 1 column volume of the same buffer. 
Fraction were tested for proteolytic activity using the LysM_CHAP construct as 
described before.  
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Results 
Molecular dissection of the phage lysin PlySK1249. To assess the specific role of 
each of the predicted domains of PlySK1249, different truncated forms of the enzyme 
were cloned in E. coli, overexpressed and purified via 6X-His Tag affinity (Figure 1.A 
and 1.B). In this series, the amidase domain (Ami) could be overexpressed alone or in 
conjunction with the LysM CWBD, generating Ami_LysM, whereas the CHAP domain 
could never be obtained alone and needed the continuity with LysM to be produced 
(Figure 1.A). Therefore, CHAP could not be tested alone. All the other domain 
combinations were sucessfully produced. The puritiy and correct molecular weight 
following expression and affinity purification was verified on 4-12% BisTris gels (Figure 
1.B).  Bands were present at the expected molecular weights (~54 kDa for PlySK1249, 
~19 kDA for Ami, ~37 kDA for Ami_LysM, ~26 kDA for LysM_CHAP and ~13 kDa for 
the CWBD LysM).  
 
Lytic effect on whole bacterial cells. The relative contribution of the two CDs and 
the CWBD to bacterial lysis was compared to that of the parent enzyme. The constructs 
were first tested against an array of different Gram-positive bacteria (Figure 1.C). The 
decrease in turbidity of bacterial suspensions was measured after 30 min using 
equimolar concentrations (1 µM) of each construct.  The parent enzyme had greater 
lytic activity against Streptococcus spp. than against more distantly related species 
such as enterococci. Moreover, the truncated forms were always less lytic than the 
parent enzyme and demonstrated a progressive decrease in lysis from Ami_LysM to 
Ami, followed by LysM_CHAP, which was not lytic at all even after 2 h of incubation 
(results not shown). Similar results were observed with purified cell wall (see 
Supplementary Figure 1). 
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We further tested possible synergistic effects between the Amidase and CHAP 
domains when applied separately or together on S. dysgalactiae cultures. Figure 1.D 
confirms the decrease in intrinsic lytic activity of the different subdomains observed in 
Figure 1 C. While the parent lysin inflicted a rapid 50% drop in turbidity in 5 minutes, 
Ami_LysM showed intermediate lysis (50% turbidity drop in 1 h) and LysM_CHAP was 
not lytic at all. However, adding equimolar amounts of non-lytic LysM_CHAP to 
Ami_LysM increased lysis substantially and adding 100 times more LysM_CHAP 
restored lysis almost completely after 60 minutes compared to Ami_LysM alone. In 
addition, these results correlated with a parallel drop in viable counts as depicted in 
Figure 1.E. Thus, although CHAP had no intrinsic lytic activity, it clearly contributed to 
cell lysis by Ami_LysM to mimic the parent enzyme. This was also corroborated by 
combining LysM_CHAP with the Ami construct (Supplementary Figure 2). 
A closer look at LysM_CHAP effects by optical and electron microscopy also revealed 
more subtle non-lytic effects (Figure 2). First, adding LysM_CHAP to S. dysgalactiae 
cultures composed of 90% chains of 7 to 37 cells resulted in chain disruption after 1h 
(60% of cells were composed of 2 subunits) (Figure 2.A). Second, light and EM pictures 
of cells treated with LysM_CHAP revealed cell swelling and surface alteration, without 
genuine lysis (Figure 2.B). Thus, although non-lytic, LysM_CHAP did have a sub-lytic 
effect resulting in morphological alterations.  
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Figure 1. Lytic activity characterization of the PlySK1249 lysin and its different truncated forms. 
A) Parent PlySK1249 (full enzyme, aa 1-489); Ami (N-terminal amidase, aa 1-170); Ami_LysM (N-
terminal amidase + LysM, aa 1-330); LysM_CHAP (LysM + C-terminal CHAP domain, aa 250-489); 
LysM (central CWBD, aa 220-330). B) SDS-PAGE gel showing PlySK1249 and its different truncated 
constructions. The purified lysin constructions were loaded (2 mg/ml) on NuPAGE 4-12% BisTris and 
stained with Coomassie blue. Molecular mass was determined with a pre-stained protein standard. C) 
Cells of different bacterial species in the exponential growth phase were exposed to 1 µM of parent 
PlySK149 or its different truncated forms. Decrease in cultures’ turbidity was measured at 600 nm after 
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30 min. No decrease in turbidity was observed in the absence of enzyme (not shown) or in the presence 
of LysM_CHAP. D) S. dysgalactiae cells in the exponential growth were also exposed to 1 µM of 
Ami_LysM or LysM_CHAP constructs alone or in combination the decrease in turbidity (at 600 nm) was 
followed over for 1 h. E) Viable counts in experiment D) were assessed by plating serial dilutions on 
nutrient agar. The experiments were repeated twice in triplicate and means ± standard deviations are 
shown. 
 
Hydrolytic effect on purified cell walls. We first determined the glycosidase or 
peptidase nature of the PlySK1249 enzyme on purified S. dysgalactiae cell wall (see 
Supplementary Table 2). As predicted by bioinformatic analysis, no glycosidase activity 
was revealed by the Park-Johnson assay run with either the parent enzyme or its 
different constructs. In contrast, glycosidase activity was indeed present in the control 
experiment with the muramidase mutanolysin. 
On the other hand, amidase or endopeptidase activities were detected in all the 
constructs by measuring concentrations of free amino groups after peptidoglycan 
hydrolysis using a modified Ghuysen assay. Although control mutanolysin produced a 
low level of free amino groups (around 0.1 mM), the PlySK1249 and its different 
catalytic domains produced 50 to 100 times more (between 5.7 and 11.4 mM). Thus, 
PlySK1249 carried purely amidase or peptidase activities, including when its non-
bacteriolytic CHAP domain was used alone (see Supplementary Table 2). 
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Figure 2. Morphological aspect of cells lysed by the PlySK1249 lysin and its different truncated 
forms. A) S. dysgalactiae in the exponential growth phase were observed after one hour using 
phosphate buffer as a control (A.I) or LysM_CHAP at a final concentration of 3.5 µM (A.III). Although 
the CHAP domain did not impact directly on cell lysis, an effect on chain disruption was observed. The 
control population was composed at 90% of chains of 7 to 37 cells for the control (144 cells observed in 
total, A.II) compared to the 60% of chains composed of two cells for the LysM_CHAP treatment (1044 
 103 
 
cells observed in total, A.VI). B) Transmission electron microscopy of S. dysgalactiae cells treated with 
the native PlySK1249 lysin or its different truncated versions. S. dysgalactiae cells in the exponential 
growth phase were treated with (B.I) phosphate buffer for 1 h as a control, (B.II) Plysk1249 for 15 min, 
(B.III) Ami_LysM for 15 min, or (B.IV) LysM_CHAP for 1 h. Cells were then post-fixed using 
glutaraldehyde and embedded in epoxy for ultrathin sectioning. Scale bar represent 500 nm.  The inset 
in figure (B.IV) highlights the non-lytic wall nibbling by the CHAP endopeptidase.      
 
Dissection of the amidase and endopeptidase activities. To discriminate between 
the activities of the Ami and CHAP domains, purified wall-peptidoglycan was digested 
with each of the constructs and the released peptides were fractionated by RP-HPLC, 
before structural analysis by LC-MS (see next section). If amidase activity was present, 
glycan chains are expected to be cleaved from the peptides, which could be analysed 
by RP-HPLC. If only endopeptidase activity was present, the peptides are expected to 
remain attached to the glycan part and be lost during the step of sequential 
precipitation (see Methods section and Figure 3.A). In addition, a strong correlation 
between peak retention times and the chemical structure of the muropetides exists 
which can give information on their structure; low molecular weight monomeric 
muropeptide tend to elute first and high molecular weight muropetide like trimers to 
pentamers elute last [122]. 
After digestion with the parent enzyme, which contains both amidase and peptidase 
(CHAP) predicted domains, the released peptides revealed two major peaks with 
relatively short retention times (ca. 35 and 40 min, Figure 3.B). This presumably 
represented simple stem peptides, such as monomers and dimers, resulting from a 
dual amidase and endopeptidase peptidoglycan digestion.  
After digestion with Ami or Ami_LysM alone, the two major peaks became marginal 
and were replaced by an array of smaller peaks appearing later (ca. 55 min, Figure 
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3.C and 3.D). Because of their longer retention time, they were likely to represent 
peptides of higher complexities resulting from pure amidase digestion, which 
disconnects the glycans without further fragmenting stem peptide polymers. Of note, 
the identical profiles obtained for Ami and Ami_LysM also tend to invalidate the 
hypothesis that the CWBD could be directly implicated in the hydrolytic activity of the 
enzyme. 
 
 
 
Figure 3. RP-HPLC chromatogram of S. dysgalactiae peptidoglycan digested with PlySK1249 or 
its truncated catalytic domains. A) Purified wall-peptidoglycan was digested ON and glycans were 
sequentially precipitated before chromatography on a C18 Sephasil column. Equimolar concentrations 
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(3.5 µM) of B) PlySK1249, C) Ami, D) Ami_LysM, E) LysM_CHAP and F) both Ami_LysM and 
LysM_CHAP were used and analyses were repeated three times with the same results. 
 
After digestion with LysM_CHAP alone, no peptide peaks appeared in the 
chromatogram (Figure 3.E). According to the positive result of the Ghuysen test that 
clearly demonstrate peptidase activity for the CHAP domain (see Supplementary Table 
2), the absence of peaks can be attributed to an endopeptidase. Indeed, the hydrolysis 
of the peptide cross bridge resulted in peptides that are still attached to the glycan 
fraction, which is lost during the sequential glycan precipitation. In addition, the 
synergism observed with cell lysis when Ami_LysM and LysM_CHAP were mixed in 
equimolar concentrations was also confirmed on purified cell wall with digestion 
patterns similar to the native enzyme (Figure 3.B and 3.F). Thus, even though 
LysM_CHAP was not able to solubilize the cell wall on its own, it did substantially 
contribute to complete digestion, most likely by trimming the peptide polymers 
generated by Ami_LysM, just as it potentiated the lytic activity of Ami_LysM in bacterial 
cell lysis assays (see Figure 1.D). 
 
LC-MS analysis of peptide fragments. The endopeptidase hydrolytic activity of the 
CHAP domain could be demonstrated, but it still not explained why the domain was 
not directly lytic on its own since many lysin with endopeptidase activity are known to 
lyse bacteria efficiently. To this end, we further characterized the structures and 
hydrolysis sites of the peptides generated by cell wall digestion with either the parent 
enzyme or the Ami-LysM construct using LC-MS (Figure 4). For better comparisons, 
samples were analysed in the same injection batch and with a smooth elution gradient 
to separate potential isobaric precursors. The presence of precursor masses 
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containing the stem peptide motif AQKAAA and polymers of it was then assessed in 
both samples. De novo peptide sequencing of the observed masses allowed deducing 
their structures. 
Potential monomers, dimers, trimers, quadrimers and heptamers were detected, but 
with great quantitative variability between the parent enzyme and its Ami_LysM 
construct (Figure 4.A and 4.B and Supplementary Figure 3).  Indeed, digestion with 
the bifunctional parent lysin surprisingly not resulted in the production of monomers 
(4.8%) but principally in dimers (90.2%). In comparison, digestion with Ami_LysM 
generated an array of more complex peptides dominated by trimers and tetramers 
(48.3% and 34.3%, respectively), with a minority of dimers and heptamers (11.5% and 
5.6%, respectively).  
Taken together, these results suggest a N-acetylmuramoyl-L-alanine amidase activity 
for the Amidase domain and a L-Ala-D-Ala endopeptidase activity for the CHAP 
domain (Figure 4.C). More importantly, the PlySK1249 lysin was not observed to 
produce monomer peptide but mostly dimer, which signifies that the CHAP domain 
cannot resolve dimeric structure but rather more complex ones like trimers to 
heptamers.  This also explains why the CHAP domain is not directly lytic, since the 
glycan strands can still remain connected though dimer crosslinks, which is sufficient 
maintain a polymer structure and prevent bacterial lysis.  
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Figure 4. LC-MS analysis of S. dysgalactiae wall-peptidoglycan digested with PlysSK1249 or 
Ami_LysM. A) The digestion products of the native enzyme and its truncated Ami domain were 
analysed by LC-MS after a 5 kDa filtration. Precursor masses corresponding to dimer, trimer, quadrimer 
and heptamer of the AAAQKA monomer block were detected. All of them, at the exception of the 
heptamers, which were only present in the amidase digestion, were detected in both samples. Polymer 
structures could be deduced from masses after de novo peptide sequencing. B) Relative abundance of 
the different polymers observed in the native enzyme and amidase domain digestion. C) Representation 
of S. dysgalactiae peptidoglycan according to the masses and sequences observed. Arrows indicate 
the cleavage sites for the respective catalytic domains of the enzyme. The dotted line framed area 
corresponds to the dimer block. 
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Role of the LysM CWBD. Many lysins carry CWBDs, which are believed to position 
the CDs in the cell wall and to determine the enzymes’ strain specificity. To investigate 
the contribution of LysM to the binding of PlySK1249 to bacterial cells, an ELISA was 
performed with its different constructs using the C-terminal 6X-His Tag of the 
constructs as an epitope.  
The binding capacities of the parent enzyme and the truncated constructs were 
concentration dependent (Figure 5A and Supplementary Figure 4). Moreover, 
comparing binding-affinities of Ami_LysM and Ami indicated that the presence of LysM 
conferred greater binding capacity than amidase catalytic site alone thus confirming 
the assumption that CWBDs are important for cell binding.  
Nonetheless, further measurements of the Ami and LysM binding affinities indicated 
that the amidase domain alone also had intrinsic binding capacities. Indeed, LysM was 
less prone to bind bacterial cells on its own (Figure 5.B). Moreover, when tested on 
different bacterial strains, LysM alone displayed a monotonous low level of binding, 
whereas Ami showed greater binding as well as strain specificity. Hence, Ami and 
LysM cooperate for cell binding, Ami ensuring strain specificity and LysM increasing 
overall binding but only in the presence of Ami. 
Finally, the binding capacity of the LysM_CHAP was 1000 time lower than that of 
Ami_LysM (Supplementary Figure 4B), reinforcing the Ami and LysM functional 
relationship. 
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Figure 5. Cell binding capacity and diffusion of PlySK1249 and its amidase and CWBD domains. 
A) Bacterial cells in the exponential growth phase were diluted to 108 cells per ml, adsorbed to a 96-well 
plate and exposed to different concentrations of Ami or Ami_LysM. The capacity of the enzyme to bind 
to coated-wells was assessed by adding an anti-His antibody that was coupled to peroxidase. The signal 
was read at 450 nm and the control measure was performed on adsorbed bacteria without the addition 
of enzyme. B) Different streptococcal species were used in the same way to test the affinity of either the 
Ami or LysM domains at 3 µM. C) Diffusion of the amidase domain in bacteria embedded in agar 
compared to the Ami_LysM construct and the native enzyme using a concentration of 40 µM and 
different streptococcal species. D) Diffusion of the Ami and Ami_LysM constructs regarding different 
concentration. E) Example of diffusion halos observed with S. dysgalactiae at 40 µM. All experiment 
was repeated three times. Means ± standard deviations are shown. 
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Interference of cell binding with extracellular spread of lysins. Although LysM 
increased wall binding and enhanced bacterial lysis, the cell wall-binding property does 
not exclude other functions, such as lysis regulation. In the following experiments, we 
tested the possibility that the binding domain could prevent the diffusion of the 
enzyme,, as previously suggested [92, 93], possibly to protect neighbouring cells from 
“lysis-from-the-outside” and preserve already infected cells from prophage abortion, or 
not yet-infected cells from new rounds of phage infection. To test this hypothesis, we 
measured the diffusion of the amidase domain (Ami) with and without the LysM CWBD 
across bacteria packed in soft agar. Because of the lytic activity of the amidase domain, 
it was possible to quantify diffusion by measuring the diameter of the clear halo 
produced by bacterial lysis (Figure 5.C to 5.E). Figure 5.C shows that the presence of 
the LysM CWBD clearly prevented diffusion of the Ami-induced lysis in agar containing 
susceptible strains (diameter decrease 2.5 cm to c.a. 1cm) compared to the Ami alone. 
Moreover, the lower diffusion of Ami_LysM was similar to that of the parent enzyme, 
indicating that the phenomenon was valid for the natural version of the lysin as well, 
and not related to the protein size. In the same vein, Figure 5.D shows that diffusion of 
the Ami domain was concentration dependent, whereas the presence of LysM 
prevented diffusion over a >100 times concentration range (Figure 6.D). Thus, the 
CWBD strongly prevented diffusion of the enzyme and potentially protected 
surrounding bacteria.       
 
Proteolytic cleavage of PlySK1249 in the presence of cell wall protein extract and 
trypsin. In addition to hampering enzyme diffusion via bacterial wall binding, the 
enzyme was also observed to be degraded when incubated ON with cell wall protein 
extract (Figure 6.AI). Due to the large amount of proteins in the protein cell wall extract, 
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visualization of the degradation products was not directly possible on a SDS gel and for 
this reason western blotting with 6X-His Tag antibody was used. After ON incubation, 
two bands at c.a. 30 and 20 KDa were generated, which were absent in the control with 
the lysin only.  No degradation product was observed when Ami_lysM was tested alone. 
In contrast, digestion of LysM_CHAP produced one specific band at 20 KDa (Figure 
6.AII and 6.AIII). It is to note that degradation was first observed with lysed bacteria, but 
due to the few signal obtained after prolonged exposition of the blot it was decides to 
use cell wall protein extract (results not shown). 
In order to study the proteolytic degradation in a more controlled environment, we also 
used trypsin and mixed it with the native PlySK1249 enzyme in the presence of purified 
cell wall. Figure 6 shows that the trypsin cleavage generated two main products (bands 
1 and 2 in Figure 6B), which were confirmed by amino acid sequencing. Band 1, with 
the higher molecular weight, corresponded to the amino acid sequence ranging from aa 
1 to 317, which encompassed the amidase catalytic domain plus LysM. Band 2 
corresponded to the CHAP catalytic domain (aa 317 to 489). Western blot using a 6X-
His Tag antibody also confirmed the presence of the C-terminal part of the enzyme 
(CHAP domain, Figure 6.C).  
In addition, the native enzyme and its different truncated version were also digested with 
trypsin during different time points with or without purified cell wall (Figure 7). 
Interestingly, the presence of the substrate was shown to have an impact, with 
modification in the trypsin degradation patterns. Indeed, in absence of peptidoglycan 
substrate, the digestion pattern was different from the one observed in figure 6.B with 
the production of only one band at a size of c.a. 20 KDa (Figure 7.A). This actually 
suggested that the c.a. 40 KDa band corresponding to the Ami_LysM domain was less 
stable in absence of substrate. The hypothesis was confirmed in Figure 7.B, which 
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shows that the Ami_LysM construct is resistant to proteolysis in presence of purified 
cell. In addition, the LyM_CHAP domain was proteolysed with a similar pattern in 
presence or absence of substrate (Figure 7.C) and the Ami domain was not observed 
to be proteolytically degraded in this conditions (Figure 7.C). This highlight the fact that 
the protein is composed of different proteolytic resistant cores that correspond to the CD 
and CWBD domains and that the linker connecting the Ami CD to the LysM CWBD is 
more resistant to degradation when the enzyme is in contact with its peptidoglycan 
substrate. Of note, the trypsin western blot profiles were also similar to the one observed 
with cell wall protein extract for the LysM_CHAP and Ami_LysM constructs (Figure 6.AII, 
6.AIII compared to Figure 8B, 8C, respectively). However, for the PlySK1249 a second 
band at 30 KDa was not present in the ON trypsin digestion compared to cell wall protein 
digestion (Figure 6.A compared to 6.C). The pattern was more similar to one observed 
with trypsin after 1 to 10 minutes, which could suggest imperfect digestion when using 
cell wall extract for the native enzyme. 
In order to identify to protease responsible for the PlySK1249 degradation, we finally 
performed fractionation of the protein content present in the cell wall of the S. 
dysgalactiae strain. Ammonium sulphate was used to make a first sorting and fractions 
were tested on the LysM_CHAP construct with a higher proteolytic activity observed for 
60% to 75% concentrations (Figure 9.A). A second purification step was performed by 
size exclusion chromatography using a 55% to 80% ammonium sulphate fraction and 
the output was again tested for proteolytic activity on the LysM_CHAP construct (Figure 
9.BI and 9.BII). Fractions B9 will now be used for proteomic content analysis in order to 
observe protease enrichment compared to fraction B5 were no activity was present.  
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Figure 6. PlySK1259 and its truncated forms proteolysis in presence of protein cell wall extract.  
A) 40 µM of the parent enzyme (I), Ami_lysM (II) or LysM_CHAP (III) were incubated overnight with cell 
wall protein extract form S. dysgalactiae. Samples were migrated on NuPAGE 4-12% BisTris and 
degradation was confirmed by western blotting using the 6-his tag. B) 40 µM of the parent enzyme was 
incubated ON with 0.1 uM/ml of trypsin and 100 ug/ml of purified S. dysglactiae cell wall ON. Sample 
were migrated on NuPAGE 4-12% BisTris and stained with Coomassie blue. Protein degradation was 
observed in the presence of the substrate and bands 1 and 2 were sequenced. The N-terminal part of 
the protein encompassing the amidase domain plus LysM CWBD was detected in band 1 and the C-
terminal with the CHAP domain part in band 2. C) Degradation was also confirmed by western blotting 
using the 6-His tag. 
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Figure 7. PlySK1259 and its truncated forms proteolysis in presence of Trypsin.  A) 40 µM of the 
parent enzyme (I), Ami_lysM (II), LysM_CHAP (III) or Ami (IV) were incubated during different time 
points with 1 µM/ml of trypsin and with or without 100 µg/ml of purified S. dysgalactiae cell wall. 
Sample were migrated on NuPAGE 4-12% BisTris and stained with Coomassie blue. 
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Figure 8. Western blot of PlySK1259 and its truncated forms proteolysed in presence of protein 
cell wall extracts.  40 µM of the parent enzyme (A), LysM_CHAP (B) or Ami_lysM (C), were incubated 
during different time points with I µM/ml of trypsin and with or without 100 µg/ml of purified S. 
dysgalactiae cell wall as in figure 7. Samples were migrated on NuPAGE 4-12% BisTris and degradation 
was confirmed by western blotting using the 6-his tag. 
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Figure 9. Protein content fractionation of S. dysgalactiae SK1249 total cell wall extract using 
ammonium sulphate precipitation and size exclusion chromatography. A) Proteins present in the 
total cell wall extract were serially precipitated by increasing steps of sulphate ammonium. Between 
each step, proteins were collected by centrifugation and the mixed with 40 µM of the LysM_CHAP 
construct and incubated ON. Samples were then migrated on a NuPAGE 4-12% BisTris and degradation 
was confirmed by western blotting using the 6-his tag. B.I) The 55% to 80% ammonium sulphate 
precipitation fraction was further separated using size exclusion chromatography. B.II) 500 yl fraction 
were tested for activity as described before.    
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Discussion and perspectives 
Phage lysins are ubiquitous and prone to be dispersed in relatively large quantities in 
the microbial environment. Much has been learned about the timing of phage-mediated 
cell lysis and its complex control, with regulation taking place at lysin/holin expression, 
lysin translocation and lysin activation (for review, see [101, 123, 124]). However, less 
is known about their structure-activity relationship, their regulation during cell wall 
hydrolysis, and their fate once liberated in the surrounding.  
Here we addressed the issues of lysin multi-modularity, bacterial specificity, and 
prevention of accidental lysis of neighbouring bacteria in the S. dysgalactiae prophage 
lysin PlySK1249. We first asked whether PlySK1249 needed all its three domains (two 
CDs and one CWBD) for effective lysis of its natural host bacterium. Using the parent 
enzyme and a variety of truncated constructs, we found that all three domains 
cooperated to increase the overall lytic activity of the parent enzyme, independently of 
their own intrinsic lytic activities. For instance, while CHAP_LysM was non-lytic, it 
synergized with amidase toward restoring the lytic activity of the parent enzyme. 
Likewise, the non-enzymatic CWBD LysM enhanced amidase-induced lysis, most 
likely by positioning the amidase appropriately in the cell wall, as proposed elsewhere 
[112]. Thus, although CHAP and LysM were not intrinsically bacteriolytic, they did have 
an effect when combined in the context of the multi-modular parent enzyme. In 
particular, the CHAP-amidase inter-domain synergism is a new observation. Moreover, 
although CHAP was not macroscopically lytic on whole bacteria, it had observable 
effects by optical and electronic microscopy. CHAP could resolve S. dysgalactiae 
chains to individual cells and nibble walls from the outside generating notched 
surfaces, although bacteria did not lyse or die.  
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To better understand the roles of amidase and CHAP in this synergism we investigated 
their individual hydrolytic activities during peptidoglycan digestion. Both amidase and 
CHAP yielded free amino groups compatible with their predicted amidase and 
endopeptidase activities. In contrast, no glycosidase activity was detected for either 
the whole enzyme or its truncated constructs.  
We then studied their contribution to cell wall solubilisation by analysing the cut-out 
patterns of stem peptides during peptidoglycan digestion. We found that the ability of 
the parent enzyme to solubilize purified walls and digest their stem peptides resulted 
from the addition of its two catalytic domains: i.e. amidase disconnected glycan chains 
from the stem peptides but could not resolve peptide crosslinks, whereas CHAP 
resolved cross-linked stem peptides but was unable to disconnect glycans from 
peptides. Hence, as in cell lysis, the cooperation between the two domains was 
apparent. However, the endopeptidase activity measured for the CHAP catalytic site 
was still in conflict with its apparent inability to solubilize the walls on its own or lyse 
whole cells. 
Cell lysis results from peptidoglycan digestion that must be extensive enough to allow 
the intracellular turgor pressure to burst the cell. In the present case, the CHAP of 
PlySK1249 did not resolve the stem peptides to monomers, but mainly to dimers, which 
are likely enough to maintain a loose glycan-peptide meshwork that can prevent total 
wall solubilisation and thus cell lysis. Interestingly, similar observations were made with 
the Lc-p75 and Msp1 Lactobacillus autolysins, which endopeptidase activities were 
observed to have a preference for tetrapeptide over tripeptide [125, 126].  
Thus, although silent in terms of cell lysis senso stricto, CHAP was a genuine 
endopeptidase companion of amidase, and thus was not an inactive evolutionary 
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byproduct on the way to be lost, as sometimes suggested [85, 86]. The whole enzyme 
profited of these interactions. 
Second, we asked whether LysM was a determinant of bacterial host specificity, in 
addition to promote lytic synergism between amidase and CHAP. But this was not the 
case. CWBD bound the walls of an array of streptococcal and other Gram-positive 
species with similar affinities, whereas it was the amidase domain that determined 
species specificity.  
 
 
 
 
Figure 10 Proposed model for post-lysis lysin regulation. After induction of the integrated prophage 
(A), the lysin is produced during the replicative cycle (B). Cell lysis is controlled by the production of 
holin at the end of the replicative cycle, which permits the diffusion of the enzyme through the plasma 
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membrane to its peptidoglycan substrate (C). After cell wall degradation, the lysin get proteolysed by 
cell wall associated proteases and the diffusion of the active amidase domain is prevented by the CWBD 
(C, D). The second catalytic domain is released but has no direct impact on the surrounding cells, which 
can be in a different phase of its replicative cycle (E.I), new pray (E.II) or where the prophage can be 
still integrated (E.III). 
 
We next asked whether wall attachment of lysins could have other roles, such as 
contributing to retaining the enzyme around the bacterium after cell lysis, and thus 
preventing uncontrolled diffusion and lysis-from-the-outside of neighbouring bacteria, 
as suggested [92, 93]. We identified such a role using a diffusion assay. While amidase 
alone could readily diffuse and lyse cells at a distance, the LysM-containing parent 
PlySK1249 and Ami_LysM enzymes could not diffuse, as they were retained around 
lysing cells by the LysM domain. This CWBD-related wall-retention persisted over 100-
time concentration titrations, whereas such a titration drastically increased the diffusion 
of the amidase domain alone, thus experimentally supporting the hypothesis of in situ 
lysin blockage [92, 93]. 
If lysin control is as important, then it should be as thorough as possible. To this end 
we investigated the fate of the enzyme during peptidoglycan digestion. Most strikingly, 
we observed that, in the process of wall digestion, PlySK1249 underwent proteolytic 
cleavage. The cleavage site, either by cell wall protein extract or trypsin, was observed 
to be very specific and generated in the case of trypsin an Ami_LysM and CHAP 
moiety. Interestingly, it was already observed that the main autolysins AtlA for E. 
faecalis and AcmA in Lactococcus lactis were also degraded by extracellular proteases 
[127-129]. Both enzymes process also LysM domain and cleavage was observed to 
take place in the linkers that connect them by the HtrA serine protease in the case of 
L. lactis. A Truncated version of the AcmA that does not have its lysM domain was also 
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observed to be less active and thus it was hypothesize that proteolytic cleavage could 
play a role in controlling cell wall degradation during cell division. According to our 
preliminary results, which have to be proofed in vivo, we would make the hypothesis 
that the PlySk1249 proteolytic cleavage observed is the key aspect that can reunify 
the apparent contradiction of having a non-lytic domain. Indeed, proteolysis would 
simply stop the intramolecular synergism of both CD and create a still lytic Ami_LysM 
domain that remains avidly bound to digested walls debris, discouraging the enzyme 
from diffusion (see diffusion experiment above), while non-lytic CHAP that is 
supposedly harmless for neighbouring bacteria.  
However, while binding the wall curbs Ami_LysM, CHAP might not be a useless 
bystander. The CHAP de-chaining activity is reminiscent of cell wall maturation by 
autolysins in Bacillus subtilis, which are also acting as de-chaining enzymes, as well 
as the Cse autolysin of Streptococcus thermophilus that is composed of a LysM and 
CHAP domain that promote cell separation [130, 131]. If CHAP is a de-chaining 
enzyme, one might speculate that it could help separate intact cells from the ones 
undergoing lysis, thus removing them from the risk of lysis-from-without and adding 
another level of protection. 
In summary, the present observations provide logical explanations for the multi-
modular architecture of PlySK1249 and the functionality of its various domains. 
Although all domains cooperate for lysis of host bacteria, they have specific roles that 
are summarized in the model proposed in Figure 10. First, amidase is the main lytic 
domain responsible for both bacterial lysis and host cell specificity. Second, LysM 
mediates PlySK1249 attachment and positioning in the wall, but also impairs diffusion 
of the enzyme that may be detrimental to surrounding bacteria. Finally, cleavage of the 
lysin during peptidoglycan digestion by serine protease present in the periplasmic 
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space or in the cell wall completes the intrinsic lytic regulation aimed at protecting 
closely related neighbouring cells from lysis-from-without. While the model complies 
with the observations reported herein, it also opens new areas to understand the subtle 
intra-molecular functioning of phage lysins. Moreover, it raises questions about the 
ideal architecture of therapeutic antibacterial lysins, where the presence of CWBDs 
might be detrimental for the diffusion of the enzymes within infected sites.  
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Supplementary data 
 
Supplementary table 1: Bacterial strains and their origins, plasmids and nucleotides 
Bacterial strains Characteristics Origin 
   
E. coli    
BL21(DE3)pLysS F- ompT hsdSB (rB - mB-) dcm+gal (DE3) 
pLysS (Camr ) 
Stratagene 
BL21/pPlySK124928a E. coli BL21 (DE3) (pLysS) transformed with 
pPlySK124928a 
[80] 
BL21/pAmi28a E. coli BL21 (DE3) (pLysS) transformed with 
pAmi28a 
This study 
BL21/pAmi_LysM28a E. coli BL21 (DE3) (pLysS) transformed with 
pAmi_LysM28a 
This study 
BL21/pLysM_CHAP28a E. coli BL21 (DE3) (pLysS) transformed with 
pLysM_CHAP28a 
This study 
BL21/pLysM28a E. coli BL21 (DE3) (pLysS) transformed with 
pLysM28a 
This study 
   
Streptococci   
S. dysgalactiae 
SK1249 
Human, haemoculture K. Mogens 
S. agalactiae FLS-S3-
026 
Bovine  M. Stanhope 
S. agalactiae 17-2167 Human, endocarditis CHUVb 
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S. agalactiae 532 Human G. Jordan 
S. agalactiae GF Human, haemoculture  F. Gilliand 
S. pyogenes ATCC 
19615 
Human, sore throat R.G. Wittler 
S. gordonii DL1 Human H.F. 
Jenkinson  
S. mutans ATCC 
25175 
Human, carious dentine DSMZc 
S. suis #19 Porcine M. Haenni 
S. uberis ATCC 
700704 
Bovine ATCCd 
S. pneumonia D39 Human J. McCuller  
   
Enterococci   
E. faecalis ATCC 
29212 
Human, urine Micro-Media 
Systems, Inc 
E. faecium D344 Human J. Entenza 
   
Plasmids  Characteristicsa Origin 
   
pET-28a Expression vector; Kanr Novagen  
pPlySK124928a pET-28a carrying PlySK1249  [80] 
pAmi28a pET-28a carrying Ami This study 
pAmi_LysM28a pET-28a carrying Ami_LysM This study 
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pLysM_CHAP28a pET-28a carrying LysM_CHAP This study 
pLysM28a pET-28a carrying LysM This study  
 
Oligonucleotides 
 
Sequence 5’ → 3’, restriction enzymee 
 
Origin 
plySK28aNcoIFw 
 
plySK28aXhoIRv 
Ami28aXhoIRv 
 
Ami_LysM28aXhoIRv 
 
 
LysMCHAP28aNcoIF
w 
GCATGCCATGGGAAAACATCTAGTGATT
TGTGGACATGGGCAAGGACG 
GCCGCTCGAGTGAAATTCTAAACCAACC
TACAACTTTTCCAAGTTTAACTGTTCCAG 
GCCGCTCGAGTGTTATTGCGGACACAAG
ACCTTTCG 
GCCGCTCGAGCACACGGCTTGCAACACT
GGTTGG 
GCATGCCATGGAATCATGGGTGCTGGAG
CAGGATGTAGAAGGAAC 
 
Microsynth  
Microsynth  
 
Microsynth 
LysM28aNcoIFW 
 
GCATGCCATGGTCAAGGGGCGCACCTA
CAAAATCCTCCAAGAA 
 
Microsynth 
LysM28aXhoIRv 
 
GCCGCTCGAGCACACGGCTTGCAACACT
GGTTGGAATAGCGG 
Microsynth 
T7 
 
TAATACGACTCACTATAGGG Novagen  
T7 terminator  
 
GCTAGTTATTGCTCAGCGG Novagen 
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a Abbreviations: Camr, chloramphenicol resistance; Kanr, kanamycin resistance b Centre hospitalier 
universitaire vaudois (CHUV, Switzerland) c Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ, Leibniz-Institut, Germany) d American type culture collection (ATCC, Manassas, Virginia, USA) 
e Restriction sites are underlined. 
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Supplementary table 2. Park Johnson and Ghuysen assays for differentiation of glycosidase 
and amidase/endopeptidase activity of different PGHs against purified S. aureus cell walls 
 
reducing activity a  
[μg glucose] 
Free NH2 groups b 
[mM] 
PlySK1249 1.9 ± 25.9              8.1  ± 2.7 
Ami 13.3 ± 8.0 11.4 ± 0.3 
Ami_LysM 3.0 ± 26.0 3.0 ± 1.2 
CHAP 6.3 ± 25.0 5.7 ± 2.6 
Mutanolysin 438.4 ± 111.1 0.1 ± 0.2 
 
a Quantification of reducing groups was performed using the Park-Johnson assay. Reducing 
activity is expressed as μg glucose equivalents released in the incubation mixture. 
b The concentration of free amino groups was determined with the Ghuysen assay. 
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Supplementary Figure 1. Lytic activity of the PlySK1249 lysin and its different catalytic domains 
on purified cell wall. Decrease in turbidity was measured at 600 nm for 8 h using purified cell wall at a 
final concentration of 1 µg/ml.  
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Supplementary Figure 2. Synergistic activity between the Ami and LysM_CHAP constructs. S. 
dysgalactiae cells in the exponential growth were treated with the native enzyme or the Ami and 
LysM_CHAP constructs alone or in combination. The decrease in turbidity was measured at 600 nm for 
1 h. The experiments were repeated twice in triplicate and means ± standard deviation are shown. 
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Supplementary Figure 3. Example for the quatrimeric peptide structure sequencing. Annotated 
MS/MS spectrum (A) and fragment table (B) of peptidoglycan peptide Mr 2307.313 (m/z 577.836). They 
were obtained by de novo sequencing using PEAKS 8.0. Matched b and y fragments ions are displayed 
in blue and red respectively in the MS/MS spectrum and the table. Residue local confidence calculated 
by PEAKS is shown by sequence color: blue > 60%, purple > 80%, red > 90%. The difference between 
the theoretical and the experimental peptide mass was 1.0 ppm.  
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Supplementary Figure 4. Cell binding capacity the PlySK1249 native enzyme and the Ami_LysM 
vs LysM_CHAP constructs. Bacterial cells in the exponential growth phase were diluted to 108 cells 
per ml, adsorbed to a 96-well plate and exposed to different concentrations of PlySK1249, Ami_LysM 
or LysM_CHAP. Binding capacity of the enzyme to the wells was assessed by adding an anti-His 
antibody that was coupled to peroxidase. The signal was read at 450 nm and the control measure was 
performed on adsorbed bacteria without the addition of enzyme. The experiment was repeated three 
times. Means ± standard deviation are shown. 
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CHAPTER III 
 
The prospect of phage therapy: an example in experimental endocarditis 
due to Pseudomonas aeruginosa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Podoviridae. Negative staining. 2016. F. Oechslin 
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General introduction  
Pseudomonas aeruginosa is an ubiquitous microorganism colonizing soil, plants and 
animals. In human it is an opportunistic pathogen that can cause a variety of severe 
opportunistic infections and is highly associated with antibiotic resistance and 
nosocomial infections. In the hospital environment, P. aeruginosa is specially known 
for colonizing water systems like tap water and showers, as well as medical 
apparatuses such as respiratory equipment. The variety of infections that are 
associated with this bacterium is largely due to its virulence factor repertoire, which 
includes different proteases that can be injected by type three secretion systems. 
These enzymes have dramatic effects on epithelial barrier and wound healing (for 
review on the topic see [132]). Its ability to rapidly proliferate in damaged tissues makes 
it a primary etiologic agent in burn wound infections, resulting in high rates of mortality 
and morbidity [133, 134]. In addition, both intrinsic and acquired resistances of the 
bacterium to several classes of antibiotics make these infections often untreatable by 
conventional antibacterial agents [135]. For these reasons, the development of new 
antimicrobial strategies to control pseudomonas infections is highly warranted.  
An alternative – or complementary – strategy to antibiotherapy is the use of 
bacteriophages (phages) as new therapeutic agents. Indeed, their ability to kill their 
bacterial host by lysing them at the end of their life cycle makes them a weapon of 
choice for microbial control.  
Felix d’Hérelle co-discovered phages hundred years ago (1917) and demonstrated 
their potential for therapeutic application by successfully treating dysentery [136]. 
However, with the advent of antibiotics and antibiotic research in the 1940s, the use of 
phages quickly decreased in the Western countries. It is only in some Eastern 
European countries like Georgia that phages are still used and commercially produced 
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[137]. Recently, and along with the development of multidrug resistant bacteria, phage 
therapy was re-evaluated by the Western scientific community. Originally limited to 
research in different animal models, the evaluation process underwent a breakthrough 
in 2015 with the first human multicenter randomized phase 1-2 clinical trial Phagoburn 
(NCT02116010, http://www.phagoburn.eu) [138]. The study aimed at evaluating the 
efficacy of phage therapy in burn wounds infected by P. aeruginosa. To this end, a 
cocktail composed of twelve different anti-pseudomonas phages was manufactured by 
the Phercydes Pharma company for the clinical trial and was tested in 11 health care 
burn units located in France, Belgium and Switzerland with the Centre Hospitalier 
Universitaire Vaudois (CHUV) (http://www.phagoburn.eu).  
Taking advantage, on the one hand, of our involvement in the project and, on the other 
hand, on the long-lasting experience of our laboratory in microbial pathogenesis and 
new antibacterial therapy in animal models, we tested the Phagoburn phage cocktail 
in experimental endocarditis due to P. aeruginosa.  
Endocarditis is an inflammation of the endocardium, which is the inner layer of the 
heart. It usually involves prior sterile heart valve lesions known as vegetations, which 
are composed of fibrin-platelet meshworks prone to be infected by circulating bacteria 
[139]. Also uncommon, P. aeruginosa infective endocarditis is associated with a high 
mortality and mortality which make it an archetype of highly lethal valve infection and 
thus a good model to test new therapies [140, 141]. Although phage therapy has been 
evaluated in specific rodent infection models (mainly sepsis, pneumonia and one time 
in meningitis) [142-144], experimental endocarditis is unique in reunifying a several 
important features that could predict the human situation. First, animal endocarditis 
mimics endocarditis in humans in that bacteria are embedded in fibrin-platelet 
vegetations devoid of cellular host defences. Second, eradiation of bacteria in this 
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therapeutic sanctuary strictly depends on the intrinsic bactericidal activity of 
antimicrobial agent, not on additional immune specificities that may vary between 
animal species. Third, drug penetration into vegetation can be readily determined (i.e. 
much more easily than in organ sub-compartments), thus facilitating 
pharmacokinetic/pharmacodynamic (PK/PD) studies. Fourth, drug plasma kinetics 
mimicking those in human can be readily achieved.  
In the manuscript presented next, published in the Journal of Infectious Disease at the 
end of 2016, we studied phage therapy against P. aeruginosa experimental 
endocarditis. We report on a very substantial set of experiments both in an in vitro clot 
model mimicking cardiac vegetations and in rats with experimental aortic endocarditis. 
These include the whole continuum from susceptibility testing, resistance screening 
(as well as understanding resistance mechanisms and prevention), PK/PD profiles in 
animals (including phage penetration in infected tissues), and therapeutic assays 
including phage/drug combination therapy. Some salient findings of this work include 
the fact that although phage monotherapy was highly bactericidal, combining phages 
with antibiotics was highly synergistic both in vitro and in vivo. This was exemplified by 
an unprecedented rate of valve sterilization within 6 hours of combined-therapy in 
animals. Moreover, while phage-resistant bacterial mutants did arise in batch cultures 
in vitro, they were undetectable in the in vivo milieu. By investigating the mechanism 
of resistance, we found a tradeoff between resistance to the phage and virulence in 
the rat model, i.e. mutants that were resistant to the phage lost their infectivity. 
We believe that this report addresses a major societal challenge in healthcare, i.e. 
antibiotic resistance. First, it is uniquely comprehensive and uses the realistic model of 
endocarditis, which provides conceptual information that is valid for many deep-seated 
and systemic infections. Second, it discloses that phage-resistant bacterial mutants 
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are naturally hampered in vivo due to resistance-induced cell surface defects, i.e. 
phage-resistance is a tradeoff that affects in vivo infectivity. This provides novel 
arguments answering the legitimate worry that phage resistance might rapidly emerge 
in the clinics. Finally, the observation that a single injection of phages combined with 
antibiotics might be enough to cure infective endocarditis suggests that, if wisely used, 
phage therapy may turn into an unprecedented breakthrough in antibacterial therapy. 
 
 
The present paper was accompanied by an Editorial Commentary by Stratton et al. 
[145] and the article in the microbe magazine (January 2016, Vol 11, No 1) describing 
the relation between phage resistance and its concomitant virulence loss. 
In addition, developments along this work were awarded best poster prizes at the 
following meetings: 
- ISCVID 2015: International Society of Cardiovascular Infectious Diseases, 04-
06.06.15, Rio De Janeiro (Brazil). Best poster prize. 
 
- Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 
18-21.09.15, San Diego (USA). Best poster prize. 
 
- SGM-SSM: 74th Annual Meeting of the Swiss Society of Microbiology, 13-
15.06.16, Bern (Switzerland). Best poster prize. 
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 SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure 1. Infectivity relatedness of the different phages of the 
PP1131 cocktail. The 12 phages present in the cocktail were evaluated by statistical 
analysis regarding the similarity of their host range. A distance matrix was produced 
according to the results presented in Supplementary Table 2 and hierarchical 
clustering was used to produce a dendrogram that schematizes the similarity between 
the different phages according to their infectivity. The horizontal axis indicates relative 
distance (or dissimilarity) between phage clusters. Thus, when looking at branching 
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points (i.e. clusters), high values indicate high dissimilarity and low values indicate low 
dissimilarity. 
 
 
 
 
 
Supplementary Figure 2. Host range of the PP1131 cocktail regarding different P. aeruginosa 
isolates. The host range of the cocktail was evaluated against a panel of 33 laboratory and clinical P. 
aeruginosa isolates using a plaque assay method. By using this technique, the phage cocktail achieved 
a productive infection in 28/33 (84%) of the strains with a phage titer ranging from c.a. 6 to 10 log pfu/ml. 
Experiments were done in triplicate.  
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Supplementary Figure 3. Pharmacokinetics of phage cocktail PP1141 in uninfected rat organs.  
Phage titers were measured 6 h or 24 h after treatment onset (black and grey, respectively) in rat 
vegetations, spleens, kidneys, livers, lungs, and brains after either (A) a single i.v. bolus injection of 1010 
PFU of the cocktail or (B) the same amount of phages administered through continuous infusion. Each 
value represents the mean +/- SD from 8 to 10 individual animals. 
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Supplementary Figure 4. Alignment of pilT present in the parent strain CHA and the variant 24/2. 
Pairwise alignment using Clustal Omega. 
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SUPPLEMENTARY TABLES 
 
Supplementary Table 1. Bacterial strains used in this study. 
Pseudomonas strains Characteristics and/or source 
PAO1 Burn wound isolatea 
CHA Cystic fibrosis isolatea 
LESB 58 Cystic fibrosis , -lactam resistant, Gmr Azr Imra 
PAT2 Burn wound isolatea 
PA7 Non-respiratory human isolatea 
PA14 Wild type, UCBPP-PA14, human isolatea 
TL Clinical isolateb 
10 Bacteremiab 
83 Bacteremiab 
102 Bronchosaspirationb 
112 Peritoneal liquidb 
123 Hemocultureb 
141 Skin biopsyb 
165 Bronchoalveolar lavage b 
198 Urineb 
206 Ureteral swabb 
214 Peritoneal liquidb 
219 Hemocultureb 
253 Urineb 
247 Peritoneal liquidb 
224 Skinb 
274 Hemocultureb 
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a Kindly provided by C. Reimmann. b Isolated from different geographical areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
392 Hemocultureb 
393 Hemocultureb 
395 Hemocultureb 
401 Hemocultureb 
2062 Hemocultureb 
3292 Hemocultureb 
MI1105 Skin biopsyb 
MI1109 Skin swabb 
MI1125 Skin swabb 
MI1119 Hemocultureb 
UR1156 Urineb 
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Supplementary Table 2.  P. aeruginosa host range of individual bacteriophages 
composing the PP1131 cocktail. 
Phages 
Isolates 1 2 3 4 5 6 7 8 9 10 11 12 C 
CHA S S S S S S S S S S S S S 
LESB58 S S S R R S S S S S S S S 
PAO1 S S S S S S S S S S S S S 
PAT2 S S S S S S S S S S S S S 
PA7 R R R R R R R R R R R R R 
PA14 R R S R R S S S S S S R S 
TL S R S R S S S S S S R S S 
10 R R R R R R R R R R R R R 
83 S S S S S S S S S S S S S 
102 S R S S S S S S S S S S S 
112 S R S R S R R R R R R R S 
123 S S S S S S R S S S S S S 
141 R R S S S S S S R S S S S 
165 S S S S S R R S S R S S S 
198 R S R R R S R S R R R R S 
206 S R S S R S S S S S S R S 
214 S S S S S S S S S S S S S 
219 R S R S R R R R R R R R S 
253 S S S S S S S S S S S S S 
247 S S S S S S S S S S S S S 
224 R R S S S S R S S S S R S 
274 R S R S S S R S S S S S S 
392 S S S S R R S S R S S S S 
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393 S R S R R R S R S R R R S 
395 R R S R S S R S S S R R S 
401 S R S S S S S S S S S S S 
2062 S S S S S S S S S S S S S 
3292 R S S S S S S S S S S S S 
MI1105 S S S S S S S S S S S S S 
MI1109 S S S S S S S S S S S S S 
MI1125 S S S S R S S S R R S S S 
MI1119 S S S S S S S S S S S S S 
UR1156 R R R R R S R S R R R R S 
 
The host range of the 12 individual phages composing the PP1131 cocktail was 
evaluated against a panel of 33 laboratory and clinical P. aeruginosa isolates using the 
spot assay method. Lysis zones around phage deposits indicated phage-sensitivity 
and were recorded as “S” for Sensitive. Absence of lysis indicated phage-resistance 
and was recorded as “R” for Resistant. P. aeruginosa strain PA7 and strain 10 were 
resistant to the 12 phages of the cocktail, whereas each of the 31 remaining isolates 
could be lysed by at least two different phages. Same results were observed for the 
whole bacteriophage cocktail PP1131 (referred as C). 
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Supplementary Table 3.  Frequencies of phage resistance in in vitro fibrin clots. 
Phages Broth culture 
Clots 6 h 
Control 
Clots 24 h 
Control  
Clots 6 h 
Phages  
Clots 24 h 
Phages 
1 5.3·10-7 6.1·10-7 5.3·10-7 1.7·10-4 3.2·10-3 
2 5.9·10-7 8.7·10-8 1.7·10-7 2.5·10-4 2.1·10-1 
3 5.8·10-7 1.4·10-7 1.9·10-7 1.4·10-4 5.7·10-3 
4 5.0·10-7 3.6·10-7 2.0·10-7 2.0·10-4 1.7·10-1 
5 6.6·10-7 2.6·10-7 8.0·10-7 3.0·10-4 1.4·10-3 
6 5.1·10-7 5.6·10-7 1.7·10-7 2.7·10-4 6.8·10-3 
7 7.4·10-7 6.8·10-7 2.0·10-7 1.7·10-4 1.3·10-1 
8 5.9·10-7 2.3·10-7 8.3·10-7 2.5·10-4 1.6·10-2 
9 4.1·10-7 8.0·10-8 3.0·10-7 1.2·10-4 1.5·10-3 
10 4.1·10-7   1.2·10-6 1.7·10-7 1.4·10-4 5.9·10-2 
11 4.2·10-7 5.0·10-7 1.4·10-7 1.9·10-4 8.5·10-3 
12 7.1·10-7 6.0·10-7 3.4·10-7 1.8·10-4 8.5·10-2 
Mean 5.6·10-7 4.4·10-7 3.4·10-7 1.6·10-4 5.9·10-2 
 
The frequencies of phage resistance were measured in the bacterial populations 
isolated during in vitro phage therapy for each of the 12 individual phages of the 
PP1131 cocktail. Serial dilutions of bacteria were plated on Petri dishes with a 
saturating amount of absorbed phages (1010 PFU). 
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SUPPLEMENTARY METHODS 
 
Strains, phage cocktail and antibiotics. Strain CHA was selected for further in vivo 
studies. All strains were grown at 37°C with aeration (200 rpm) either in tryptic soy 
broth (TSB; DifcoTM, Becton Dickinson, Sparks, MD, USA) or on tryptic soy blood agar 
(TSA) plates (bioMérieux SA, Marcy l’Etoile, France). The cocktail PP1131, composed 
of 12 different phages, was manufactured and provided by Pherecydes Pharma 
(PHERECYDES PHARMA, Biocitech, Romainville, France). Ciprofloxacin (Bayer AG, 
Zurich, Switzerland) and meropenem (Labatec Pharma, Meyrin, Switzerland) were 
purchased commercially. 
 
In vitro studies. The host range of the individual phages composing the PP1131 
cocktail was determined using spot assays [34]. Experiments were done in triplicates. 
Plasma clots were prepared in 96-well microplates, as previously described [15]. The 
resulting clots (mean weight of 0.1 ± 0.01 g) were transferred into 5 ml polypropylene 
round-bottom tubes containing 500 µl of either saline (sterile solution of 0.9% NaCl in 
water), or saline plus the phage cocktail (108 PFU/ml), antibiotics (0.47 µg/ml of 
ciprofloxacin or 0.31 µg/ml of meropenem), or combinations of phages and antibiotics 
and incubated with shaking at 37°C. Clots were removed after 0, 6 and 24 h of 
incubation, washed with saline, and lysed with 25 µl of trypsin (20 mg/ml; Sigma-
Aldrich, Saint Louis, MO, USA). After 5 min of centrifugation at 14’000 rpm, the 
supernatant was removed for phage titration, and the cell pellet was resuspended in 
the initial volume of saline and plated for colony counting. The removal of supernatant 
plus the dilution procedure minimized the potential of phage carryover. Phage titers 
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were measured by plaque assays [34]. The activity of the phage cocktail was 
considered bactericidal when it killed ≥ 3 log CFU of the starting inoculum in the clot. 
 
Animal studies. Experiments were approved by and in adherence with the guidelines 
of the Swiss Animal Protection Law, Veterinary office, State of Vaud. Experiments were 
performed under license number 879.9 and in accordance with the regulations of the 
cantonal committee on animal experimentation of the State of Vaud, Switzerland. 
A mixture of ketamine (75 mg/kg) and midazolam (5 mg/kg) anaesthetics was 
administered to the animals before any surgical procedure. The production of catheter-
induced aortic vegetations and the installation of an i.v. line into the superior vena cava, 
connected to an infusion pump to deliver the phage cocktail, were performed in female 
Wistar rats as previously described [16].  
Twenty-four hours after catheterization, rats were inoculated i.v. with 108 CFU P. 
aeruginosa CHA. Eighteen hours later, animals were treated with: (i) a single i.v. bolus 
(1 ml in 1 min) of phages cocktail at 1010 PFU/ml; (ii) the same concentration of phages 
progressively infused at a pace of 100 µl/h; (iii) a single i.v. bolus (1 ml in 1 min) of 
ciprofloxacin to a total of 20 mg/kg (mimicking human-like kinetics of a single oral dose 
of 750 mg [16]) ; and (iv) a combination of single boluses of phage cocktail and 
ciprofloxacin. Ciprofloxacin was chosen for the in vivo studies because, like phages, it 
exhibits a rapid bactericidal activity. Control rats were euthanized at the onset of 
therapy and treated rats 6 h after treatment onset. 
Plasma pharmacokinetics were determined in catheterized, but uninfected rats using 
the different modes of treatment described above. For phages, blood samples were 
collected 1, 2, 6 and 24 h after phage administration. For ciprofloxacin, blood samples 
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were collected 30 min and 6 h after treatment onset. Vegetations and organs (spleen, 
liver, kidney, lung, and brain) were collected after 6 and 24 h and homogenized in PBS. 
Phage titers in plasma and organs were assessed using the plaque assay method as 
described above. Ciprofloxacin concentrations were determined by the agar diffusion 
assay with antibiotic medium 1 (Difco; Becton Dickinson), using Bacillus subtilis ATCC 
6633 as an indicator, as previously described [16]. Standard solutions were prepared 
in rat plasma.  
 
Detection and characterization of phage resistance. Bacteria grown in broth 
cultures and bacteria isolated from in vitro fibrin clots or rat vegetations were serially 
diluted and plated on blood agar plates containing 1010 PFU pre-absorbed phages. 
The procedure was done separately for each phage composing the cocktail. After 
overnight incubation at 37°C, phage-resistant colonies were enumerated. To detect 
possible slow growing colonies, plates were observed for an additional 48 h at room 
temperature. Resistance rates were determined as the number of bacteria growing on 
plates pre-adsorbed with phages divided by the number of bacteria growing on plain 
plates. Two phage-resistant variants obtained in vitro from the fibrin clots were further 
assessed for their in vivo infectivity by inoculating rats with catheter-induced aortic 
vegetations i.v. with 108 CFU of either the P. aeruginosa CHA parent strain or the 
phage-resistant variants. Eighteen hours later, rats were euthanized and bacterial 
burden in vegetations were quantified, as previously described. 
Full genomic DNA sequencing of the two phage-resistant variants and the parent strain 
CHA was performed by the core sequencing facility of the Center for Integrative 
Genomics (CIG; University of Lausanne, Switzerland) using the Pacific Biosciences 
 160 
 
RSII platform (Pacific Bioscience, Menlo Park, CA). Total DNA was extracted using the 
DNeasy Blood and Tissue kit (Qiagen, Valencia, CA, USA) according to 
manufacturer’s instructions. After assembly, open reading frames (ORFs) were 
extracted from contigs using the GenDB open source genome annotation system [37] 
and the ORFeome of the parent strain CHA was used as a reference for BLASTn [38] 
comparison. ORFs in the two mutants showing < 100% identity to ORFs present in the 
parent strain were identified and analyzed. Circular visualization for the comparison of 
ORFeomes of the parent strain and the two mutants was done using BLAST Ring 
Image Generator (BRIG) [39]. Subsurface twitching motility tests were performed as 
described [40]. LPS was extracted using the iNTRON LPS extraction kit (iNtRON 
biotechnology, Daejeon, South Korea), resolved on NuPAGE 4-12% BisTris gels 
(Invitrogen, Carlsbad, CA, USA), and silver stained according to [41]. 
 
Statistical analyses. A hierarchical clustering based on the Euclidean distance of 
binary host infection arrays was used to evaluate the similarity of the phages 
composing the cocktail. The Mann Whitney test was used to examine differences in 
bacterial or phage counts between the control and the treated groups. The Pearson 
two-tailed correlation test was used to examine the relation between phage and 
bacterial concentrations in vivo. The difference in infectivity between the wild type CHA 
strain and the resistant variants was assessed with the Fisher’s exact test. A p-value 
< 0.05 was considered as statistically significant.  
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